Document:

Exhibit 10.50

                   MERGER AGREEMENT AND PLAN OF REORGANIZATION

     THIS MERGER  AGREEMENT AND PLAN OF  REORGANIZATION  (this  "Agreement")  is
dated  as of  August  16,  2006,  by  and  among  MedSolutions,  Inc.,  a  Texas
corporation  ("MedSolutions"),  SteriLogic Acquisition Subsidiary, Inc., a Texas
corporation (the "Merger Sub"),  SteriLogic Waste Systems,  Inc., a Pennsylvania
corporation  ("SteriLogic"),  Abele-Kerr  Investments,  LLC, a Delaware  limited
liability  company and the sole  shareholder  of SteriLogic  ("Abele"),  and the
members  of Abele set forth on  Exhibit A  attached  hereto  (collectively  with
Abele, the "Shareholders," and each individually, a "Shareholder").

                                    RECITALS:

     WHEREAS, the respective Boards of Directors of MedSolutions, the Merger Sub
and SteriLogic  have each approved the merger of SteriLogic  into the Merger Sub
(the  "Merger"),  pursuant to the  Certificate  of Merger set forth in Exhibit B
hereto (the "Merger  Certificate") and the transactions  contemplated hereby, in
accordance with the applicable provisions of the statutes of the States of Texas
and  Pennsylvania,  respectively,  which permit such a merger,  contingent  upon
satisfaction  prior  to  closing  of all of the  terms  and  conditions  of this
Agreement; and

     WHEREAS,  the  parties  hereto  desire  to  make  certain  representations,
warranties and agreements in connection with completion of the Merger.

     NOW, THEREFORE, in consideration of the foregoing recitals,  which shall be
considered an integral part of this  Agreement,  and the covenants,  conditions,
representations  and warranties  hereinafter set forth, the parties hereby agree
as follows:

                                    ARTICLE I

                                   THE MERGER

     1.01 The  Merger.  At the  Effective  Time (as  hereinafter  defined),  and
subject  to  the  terms  and   conditions  of  this  Agreement  and  the  Merger
Certificate,  SteriLogic  will be merged with and into the Merger  Sub,  and the
Merger Sub will be the Surviving  Corporation.  For purposes of this  Agreement,
the  term  "Surviving   Corporation"   shall  mean  the  Merger  Sub  after  the
consummation of the Merger.  The Merger Sub's  existence,  and all its purposes,
powers,  and objectives  will continue  unaffected and unimpaired by the Merger,
and as the Surviving Corporation it will be governed by the laws of the State of
Texas and  succeed  to all of  SteriLogic's  rights,  assets,  liabilities,  and
obligations in accordance with the laws of the States of Texas and Pennsylvania,
respectively.  For federal  income tax purposes,  it is intended that the Merger
shall  constitute a reorganization  within the meaning of Sections  368(a)(1)(A)
and  368(a)(2)(D) of the Internal Revenue Code of 1986, as amended (the "Code").
Notwithstanding  any provision of this  Agreement to the  contrary,  for tax and
accounting  purposes only the Merger shall be deemed to have occurred  effective
as of July 1, 2006.

     1.02  Closing  and  Effective  Time.  Subject  to the  provisions  of  this
Agreement,  the parties  hereto shall hold a closing (the  "Closing") on (i) the
first Business Day (as defined in Article X of this Agreement) on which the last

                                       1
<PAGE>

of the conditions set forth in Article VII to be fulfilled  prior to the Closing
is fulfilled  or waived or (ii) such other date as the parties  hereto may agree
(the "Closing  Date"),  at such time and place as the parties  hereto may agree.
Immediately  upon  the  Closing,  the  parties  hereto  will  cause  the  Merger
Certificate to be filed with the respective offices of the Secretary of State of
the State of Texas and the  Secretary of State of the State of  Pennsylvania  in
accordance  with the  applicable  provisions  of the  statutes  of such  states.
Subject  to and in  accordance  with  such  statutes,  the  Merger  will  become
effective  at the date and time the  Certificate  of  Merger  is filed  with the
latter of the respective offices of the Secretary of State of the State of Texas
and the Secretary of State of the State of Pennsylvania (the "Effective Time").

     1.03 Survival of Assets and Liabilities.

     (a) All rights and  interests of each of  SteriLogic  and the Merger Sub in
and to  every  type of  property  shall  be  transferred  to and  vested  in the
Surviving  Corporation  by  virtue  of the  Merger  without  any  deed or  other
transfer. The Surviving Corporation,  as of the Effective Time of the Merger and
without any order or other action on the part of any court or  otherwise,  shall
hold and enjoy all rights of  property,  franchises  and  interests  in the same
manner and to the same extent as such rights,  franchises,  and  interests  were
held or enjoyed by each of SteriLogic  and the Merger Sub  immediately  prior to
the Effective Time of the Merger.

     (b) After the Effective Time, the Surviving Corporation shall be liable for
all  liabilities  of each of  SteriLogic  and the  Merger  Sub,  and all  debts,
liabilities,  obligations and contracts of each of SteriLogic and the Merger Sub
matured or unmatured,  whether accrued, absolute,  contingent, or otherwise, and
whether or not reflected or reserved against on balance sheets, books of account
or records of either  SteriLogic or the Merger Sub, as the case may be, shall be
those of and are hereby expressly assumed by the Surviving Corporation and shall
not be released or impaired by the Merger; and all rights of creditors and other
obligees and all liens on property of either  SteriLogic or the Merger Sub shall
be preserved unimpaired.

     1.04   Conversion  of  Shares  in  the  Merger.   Pursuant  to  the  Merger
Certificate,  at the  Effective  Time,  by virtue of the Merger and  without any
action on the part of any holder of any  capital  stock of the Merger Sub or any
shareholder  of  SteriLogic,  each share of common  stock,  par value $0.01,  of
SteriLogic  (the  "SteriLogic  Common  Stock")  which is issued and  outstanding
immediately  prior to the Effective Time held by  shareholders of SteriLogic who
do not  dissent  from the Merger  shall be  converted  into 200 shares of common
stock, par value $0.001, of MedSolutions (the "MedSolutions  Common Stock"). The
shares of  MedSolutions  Common Stock to be issued pursuant to this Section 1.04
are  referred to herein as the  "Merger  Shares."  From and after the  Effective
Time,  no shares of SteriLogic  Common Stock shall be deemed to be  outstanding,
and holders thereof shall cease to have any rights with respect thereto,  except
as provided  herein or by law. All of the Merger  Shares will be, when issued in
accordance with this Agreement,  duly  authorized,  validly issued,  fully paid,
nonassessable and free and clear of all liens, claims, pledges, options, adverse
claims or charges of any nature  whatsoever,  except as  otherwise  set forth in
this Agreement.

                                       2
<PAGE>

     1.05  Cancellation  of SteriLogic  Common Stock.  At the Effective Time, by
virtue of the Merger and  without any action on the part of any holder of shares
of SteriLogic Common Stock, all outstanding shares SteriLogic Common Stock shall
be cancelled.

     1.06 Stock  Certificates.  At and after the Effective  Time, each holder of
shares of  SteriLogic  Common  Stock  shall be  entitled  to receive in exchange
therefor, upon surrender thereof to MedSolutions,  a certificate or certificates
representing the number of whole shares of MedSolutions  Common Stock into which
such  holder's  shares of  SteriLogic  Common Stock were  converted  pursuant to
Section 1.04; provided,  however,  that certificates for the Merger Shares shall
not be  physically  delivered  to the holders of  SteriLogic  Common Stock until
after  determination of the Revenues Adjustment Amount and the EBITDA Adjustment
Amount  (each as  defined  in  Section  1.08  below),  if any.  At and after the
Effective Time,  MedSolutions  shall be entitled to treat all of the outstanding
certificates  which prior to that time represented  shares of SteriLogic  Common
Stock,  and which have not been  surrendered  for exchange,  as  evidencing  the
ownership of the number of whole shares of MedSolutions  Common Stock into which
the shares of SteriLogic Common Stock represented by such certificates have been
converted  as herein  provided,  notwithstanding  the failure to  surrender  the
certificates  representing  such interests.  The provisions of this Section 1.06
shall not apply to any shares of SteriLogic Common Stock in respect of which the
holder  thereof  pursues  the remedy of dissent  in  accordance  with 15 Pa.C.S.
ss.ss. 1571 through 1580, inclusive,  unless and until such holder has exhausted
his right of dissent thereunder,  at which time the provisions of Sections 1.04,
1.05 and 1.06 of this Agreement shall apply in their entirety thereto.

     1.07 No Fractional  Shares.  No fractional  shares of  MedSolutions  Common
Stock shall be issued in connection with the Merger.  In lieu of such fractional
shares,  any holder who would  otherwise  be entitled to receive a fraction of a
share of MedSolutions Common Stock (after separately  aggregating all fractional
shares  of stock  issuable  to such  holder)  shall be  issued,  in lieu of such
fractional shares,  cash in the amount equal to the product of the percentage of
a share of MedSolutions Common Stock such aggregate  fractional shares represent
multiplied by $1.50.

     1.08 Cash and Promissory  Note. At the Effective Time,  MedSolutions  shall
issue to Abele-Kerr Investments, LLC, to be held in trust for the benefit of all
of the  shareholders  of  SteriLogic  who do not dissent  from the  Merger,  (a)
$50,000  in  readily  available  funds  (the  "Cash"),  and  (b)  a  convertible
promissory  note (the "Note," and together  with the Merger Shares and the Cash,
the  "Merger  Consideration")  in the form  attached  hereto as Exhibit C in the
original principal amount of $250,000 with simple interest at the annual rate of
8% accruing  from the  Effective  Time and payable in 12 equal  installments  of
interest only in the amount of $1,666.67 each due monthly  beginning on the 30th
day after  the  Effective  Time,  and 24 equal  installments  of  principal  and
interest  in the amount of  $11,306.82  each due monthly  thereafter;  provided,
however, that:

     (a) the principal amount of the Note shall be reduced by a percentage equal
to the percentage of shares of SteriLogic  Common Stock held by  shareholders of
SteriLogic who dissent from the Merger; and

                                       3
<PAGE>

     (b)  beginning  with  the  first  day  of the  first  full  calendar  month
immediately  succeeding  the Effective  Time and for 12 months  thereafter  (the
"12-Month Post-Closing Period"), in the event that either

          (1) the amount of  MedSolutions'  average  monthly accrual basis sales
     (on a consolidated  basis) to SteriLogic's  customers  immediately prior to
     the Effective  Time (the "Existing  Customers") or to "Pipeline  Customers"
     (so called herein),  as such are set forth on Schedule 1.08,  (exclusive of
     any intercompany  sales between and among  MedSolutions and its affiliates,
     and any  improvements,  fees, price increases or surcharges  implemented by
     MedSolutions or its affiliates  during such 12-Month  Post-Closing  Period)
     during the 12-Month Post-Closing Period (the "12-Month Post-Closing Average
     Monthly Gross Revenues") is less than $1,200,000.00, or

          (2) MedSolutions'  earnings before interest,  taxes,  depreciation and
     amortization  on  a  consolidated   basis  ("EBITDA")  from  such  Existing
     Customers  and Pipeline  Customers  (exclusive  of any  intercompany  sales
     between and among  MedSolutions and its affiliates  (unless such affiliates
     were Existing Customers or Pipeline Customers prior to the Effective Time),
     and any  improvements,  fees, price increases or surcharges  implemented by
     MedSolutions or its affiliates  during such 12-Month  Post-Closing  Period)
     (the "12-Month Post-Closing EBITDA") is less than $300,000.00,  the greater
     of

               (i)  1.5  multiplied  by  the  difference  between  the  12-Month
          Post-Closing Average Monthly Gross Revenues and $1,200,000.00 and

               (ii)  six  multiplied  by the  difference  between  the  12-Month
          Post-Closing EBITDA and $300,000.00,

     shall be  calculated  to  obtain  an  adjustment  amount  (the  "Adjustment
     Amount"),  and such  Adjustment  Amount  shall be deducted  from the Merger
     Consideration  as follows:  25% of the Adjustment  Amount shall be deducted
     from  the  outstanding  principal  amount  of  the  Note,  and  75%  of the
     Adjustment  Amount  shall be  deducted  from the  Merger  Shares,  pro rata
     against each former holder of SteriLogic  Common Stock that received Merger
     Shares in  proportion to the  percentage  of the Merger Shares  received by
     each  such  holder,  at the  rate of $1.50  per  share;  provided  further,
     however,  that in no event shall  MedSolutions  be permitted to deduct more
     than 400,000 Merger Shares with respect to the Adjustment Amount.

     (c) In the event that  MedSolutions  ceases to provide goods or services to
any Existing  Customer  during the  12-Month  Post-Closing  Period,  the average
monthly  revenues  received from such Existing  Customer by MedSolutions  and/or
SteriLogic,  as the case may be, during the 12 months  immediately  prior to the
date on which MedSolutions  ceases to provide such goods or services  (exclusive
of  any  improvements,  fees,  price  increases  or  surcharges  implemented  by
MedSolutions or its affiliates during such period) shall be annualized, and such
annualized  amount  shall be included  within the  12-Month  Post-Closing  Gross
Revenues and the 12-Month  Post-Closing  EBITDA as if such annualized amount was
actually  received by  MedSolutions  during the  12-Month  Post-Closing  Period;
provided,  however, that such annualized amount shall not be included within the

                                       4
<PAGE>

12-Month  Post-Closing  Gross Revenues and the 12-Month  Post-Closing  EBITDA if
MedSolutions  ceases to provide goods and services to such Existing Customer due
to the  failure  of such  Existing  Customer  to pay any or all  amounts  due to
MedSolutions when and as due.

     (d) The following guidelines shall apply when determining the 12-Month Post
Closing EBITDA for purposes of this Section 1.08:

          (i) In the event that MedSolutions  merges with or otherwise  acquires
     any Existing  Customer during the 12-Month  Post-Closing  Period, an amount
     equal to the product of the aggregate amount of revenues received from such
     Existing Customer by MedSolutions  and/or  SteriLogic,  as the case may be,
     during  the  12-month  period   immediately   preceding  the  date  of  the
     consummation of such merger or other  acquisition  multiplied by a fraction
     the  numerator  of which is the number of days  remaining  in the  12-Month
     Post-Closing  Period after the date of the  consummation  of such merger or
     other  acquisition  and the  denominator of which is 365, shall be included
     within  the  12-Month   Post-Closing   Gross   Revenues  and  the  12-Month
     Post-Closing EBITDA as if such amount was actually received by MedSolutions
     during the remainder of the 12-Month  Post-Closing Period after the date of
     consummation of such merger or other acquisition.

          (ii) In the event that MedSolutions  merges with or otherwise acquires
     any Pipeline Customer during the 12-Month Post-Closing Period, MedSolutions
     shall credit $10.00 to the 12-Month  Post-Closing  EBITDA and $15.85 to the
     12-Month  Post  Closing  Gross  Revenues  for each  intercompany  sale of a
     reusable   medical  waste  disposal   container   after  the  date  of  the
     consummation  of such  merger  or  other  acquisition  attributable  to the
     operations acquired from such Pipeline Customer.

          (iii) During the 12-Month Post-Closing Period, except with the consent
     of Abele to be granted or withheld in its sole discretion, MedSolutions and
     its  Affiliates  shall not apply to the  Merger  Sub for  purposes  of this
     Section 1.08 any general and administrative expenditures or other operating
     expenses not related to the  operations of SteriLogic as they existed as of
     the Effective Time.

          (iv) During the 12-Month  Post-Closing  Period,  MedSolutions  and its
     Affiliates  shall not apply any  expenses to the Merger Sub for purposes of
     this Section 1.08 for (A) salary increases of personnel attributable to the
     Merger Sub's  operations  in excess of 5% of such  salaries as in effect at
     SteriLogic  as of the  Effective  Time,  or  (B)  salaries  for  additional
     personnel  attributable to the Merger Sub's operations in excess of that in
     effect at SteriLogic as of the Effective Time except in the ordinary course
     of business consistent with the past practices of MedSolutions.

          (v) All  payments  made to Consular,  LLC  pursuant to the  Consulting
     Agreement (as such term is defined in Section  7.02(h)  hereof) that relate
     to the existing (as of the Effective Time) New York or Systems divisions of
     SteriLogic to be merged into the Merger Sub pursuant to the Merger shall be
     applied to Merger Sub during the 12-Month Post-Closing Period.

                                       5
<PAGE>

     (e) In any instance during the 12-Month Post-Closing Period, if an Existing
Customer  requires the  replacement  of its sharps  container  system(s) and the
respective  mounting hardware therefor  (collectively,  "Equipment"),  or if the
Surviving  Corporation  replaces  any  such  Equipment  in  connection  with the
renewal,  replacement  or  extension  of a customer  contract  with an  Existing
Customer,  the Shareholders shall be liable,  jointly and severally,  for 50% of
the  Surviving  Corporation's  actual costs and expenses  incurred in connection
with the replacement of such Equipment, including without limitation the cost of
such new systems and hardware (the  "Replacement  Allocation");  the Replacement
Allocation shall be deducted from the Merger  Consideration on the date on which
the 12-Month  Post-Closing  EBITDA is  calculated  as follows:  the  Replacement
Allocation shall be deducted first from the outstanding  principal amount of the
Note,  and next from the Merger  Shares,  pro rata against each former holder of
SteriLogic  Common  Stock  that  received  Merger  Shares in  proportion  to the
percentage  of the Merger  Shares  received by each such holder,  at the rate of
$1.50 per share; provided further,  however, that in no event shall MedSolutions
be  permitted  to deduct more than  400,000  Merger  Shares with  respect to the
Replacement Allocation. Notwithstanding any provision of this Section 1.08(e) to
the  contrary,  in the  event  that the  12-Month  Post-Closing  EBITDA  exceeds
$300,000,  the Shareholders shall receive a $1.00 credit against the Replacement
Allocation  for each $1.00 by which the  12-Month  Post-Closing  EBITDA  exceeds
$300,000.

     (f) In  any  instance  during  the  12-Month  Post-Closing  Period,  if the
Surviving  Corporation is required to replace any of its regulated medical waste
containers and any  respective  mounting  hardware  therefor with respect to the
operations of the Surviving  Corporation  as in effect as of the Effective  Time
(collectively,  "Containers"),  the  Shareholders  shall be liable,  jointly and
severally,  for 1/60th of the Surviving  Corporation's actual costs and expenses
incurred  in  connection  with the  replacement  of such  Containers,  including
without  limitation the cost of such new containers and hardware,  per month for
each month remaining during the 12-Month  Post-Closing Period following the date
of such  replacement,  due in installments on each one-month  anniversary of the
Effective Time following the date such Containers are replaced (and pro rated as
appropriate if the first such installment  covers only a partial month) with the
final such  installment  due on the one-year  anniversary  of the Effective Time
(collectively,  a  "Container  Allocation");   installments  of  each  Container
Allocation  shall be deducted from the Merger  Consideration  on each  one-month
anniversary of the Effective Time as follows: such Container Allocation shall be
deducted first from the outstanding  principal amount of the Note, and next from
the Merger  Shares,  pro rata against each former  holder of  SteriLogic  Common
Stock that received  Merger Shares in proportion to the percentage of the Merger
Shares  received by each such holder,  at the rate of $1.50 per share;  provided
further,  however,  that in no event shall  MedSolutions  be permitted to deduct
more than 400,000 Merger Shares with respect to the Container Allocations.

     (g)  In  the  event  that  either  the  Merger  or  any  other  transaction
contemplated  by this Agreement  results in the  acceleration of the performance
required by, or causes the  acceleration of the maturity of, any of SteriLogic's
liabilities,  then all costs and expenses  incurred by  MedSolutions  and/or the
Surviving  Corporation  in  connection  with  securing  financing  to repay  the
accelerated  portion  of such  liabilities  shall  be  deducted  first  from the
outstanding  principal amount of the Note, and next from the Merger Shares,  pro
rata against each former holder of SteriLogic  Common Stock that received Merger

                                       6
<PAGE>

Shares in  proportion to the  percentage  of the Merger Shares  received by each
such holder, at the rate of $1.50 per share; provided further,  however, that in
no event shall  MedSolutions  be permitted  to deduct more than  400,000  Merger
Shares with respect to the Replacement Allocation.

     (h) In the event that the outstanding  principal  amount of the Note or the
value of the  Merger  Shares  is  insufficient  to  permit  the  full  deduction
allocated  thereto as set forth in this Section 1.08, any such deficiency  shall
be reallocated first to the outstanding principal amount of the Note and last to
the Merger Shares  (subject to the 400,000  share  cancellation  limitation  set
forth in this Section 1.08).  Any deduction to the outstanding  principal amount
of the Note  pursuant to this Section 1.08 shall be applied to the first payment
due thereunder and then to subsequent  payments due thereunder in  chronological
order, but the interest due shall be calculated on the adjusted principal amount
of the Note as if all such principal was deducted immediately.  No later than 30
days  after the end of the  12-Month  Post-Closing  Period,  MedSolutions  shall
provide Abele with a true, correct and complete copy of its invoice register for
such 12-Month Post-Closing Period with respect to the Existing Customers.

     1.09 Officers,  Directors; Bylaws. The officers and directors of the Merger
Sub  immediately  prior to the  Effective  Time shall serve as the  officers and
directors of the Surviving  Corporation as of the Effective  Time. The Bylaws of
the Merger Sub immediately  prior to the Effective Time shall continue to govern
as the Bylaws of the Surviving Corporation as of the Effective Time.

     1.10 Principal Office. The established offices and facilities of the Merger
Sub  immediately  prior to the Merger shall become the  established  offices and
facilities of the Surviving Corporation after the Effective Time.

                                   ARTICLE II

              REPRESENTATIONS AND WARRANTIES OF STERILOGIC AND THE
                                  SHAREHOLDERS

     To induce  MedSolutions and the Merger Sub to enter into this Agreement and
to consummate the transactions  contemplated  hereby, (i) SteriLogic  represents
and  warrants  to  MedSolutions  and  the  Merger  Sub,  and  (ii)  each  of the
Shareholders jointly and severally represent and warrant to MedSolutions and the
Merger Sub, as follows:

     2.01  Organization  and Good  Standing.  SteriLogic is a  corporation  duly
organized, validly existing, and in good standing under the laws of the State of
Pennsylvania.   Schedule   2.01  includes  (i)  a  true  and  complete  copy  of
SteriLogic's Certificate of Incorporation and all amendments thereto,  certified
by the  Pennsylvania  Secretary of State;  and (ii) true and complete  copies of
certificates of existence,  qualification  and account status,  certified by the
Secretary of State of Pennsylvania as of the Closing Date.

     2.02 Authority;  Capacity. SteriLogic has all requisite corporate power and
authority  to own its  property,  to conduct  its  business,  and to execute and
deliver this Agreement and any  instruments and agreements  contemplated  herein

                                       7
<PAGE>

that are required to be executed and  delivered  by  SteriLogic  pursuant to its
obligations under this Agreement,  and to perform its obligations  hereunder and
thereunder.  This Agreement has been approved by SteriLogic's Board of Directors
and shareholders in accordance with applicable law and has been duly authorized,
executed,  and delivered by SteriLogic.  No other corporate act or proceeding on
the  part  of  SteriLogic  is  necessary  to  authorize  this  Agreement  or the
transactions  contemplated hereby. This Agreement represents a valid and binding
obligation of SteriLogic,  enforceable against SteriLogic in accordance with its
terms, except as limited by applicable bankruptcy,  insolvency,  reorganization,
moratorium,  and similar laws  affecting the  enforcement  of creditors'  rights
generally  and the  application  of general  principles  of equity and  judicial
discretion.  Attached  hereto as Schedule 2.02 are copies of the  resolutions of
SteriLogic's  Board of Directors and  shareholders,  respectively,  certified as
true and  correct  by  SteriLogic's  Secretary,  approving  this  Agreement  and
authorizing the execution hereof by SteriLogic's President.

     Each  Shareholder  that is an  individual  has full capacity to execute and
deliver this Agreement and any  instruments and agreements  contemplated  herein
that are required to be executed and delivered by such  Shareholder  pursuant to
his  or  her  obligations  under  this  Agreement,  and  to  perform  his or her
obligations  hereunder and thereunder.  Each  Shareholder that is a corporation,
limited liability  company,  partnership,  trust or other form of entity has all
requisite  power and  authority  to execute and deliver this  Agreement  and any
instruments and agreements  contemplated herein that are required to be executed
and  delivered  by such  Shareholder  pursuant  to its  obligations  under  this
Agreement, and to perform its obligations hereunder and thereunder. With respect
to  each  Shareholder  that  is  a  corporation,   limited  liability   company,
partnership,  trust or other form of entity, this Agreement has been approved by
such  Shareholder's  Board  of  Directors  and  shareholders,  or  corresponding
governing   bodies,  in  accordance  with  applicable  law  and  has  been  duly
authorized,  executed,  and delivered by such  Shareholder,  and no other act or
proceeding  on the part of such  Shareholder  is  necessary  to  authorize  this
Agreement or the transactions  contemplated  hereby. This Agreement represents a
valid and binding obligation of each Shareholder,  enforceable against each such
Shareholder  in  accordance  with its terms,  except as  limited  by  applicable
bankruptcy, insolvency,  reorganization,  moratorium, and similar laws affecting
the  enforcement of creditors'  rights  generally and the application of general
principles of equity and judicial discretion.

     2.03 No Violation.  Neither the execution and delivery by SteriLogic or the
Shareholders  of  this  Agreement  nor the  consummation  by  SteriLogic  or the
Shareholders  of the  transactions  contemplated  hereby  will (i)  violate  any
provision  of  Title  15  of  the  Pennsylvania  Consolidated  Statutes  or  the
Certificate of  Incorporation of SteriLogic,  or the Bylaws of SteriLogic;  (ii)
except as set forth on  Schedule  2.03,  violate,  or be in  conflict  with,  or
constitute  a default (or an event or  condition  that,  with notice or lapse of
time, or both,  would  constitute a default) under, or result in the termination
of, or accelerate the performance  required by, or cause the acceleration of the
maturity  of any of  SteriLogic's  liabilities,  or  result in the  creation  or
imposition of any security interest, lien, charge, or other encumbrance upon any
of SteriLogic's  assets under,  any note,  bond,  mortgage,  indenture,  deed of
trust,  license,  lease,  contract,  commitment,   understanding,   arrangement,
agreement,  or  restriction  of any kind or character to which  SteriLogic  is a
party  or by  which  SteriLogic  may be bound  or  affected  or to which  any of
SteriLogic's  assets is  subject;  or (iii)  violate  any  statute or law or any

                                       8
<PAGE>

judgment,  decree, order, writ, injunction,  regulation, or rule of any court or
Governmental Authority (as defined in Article X of this Agreement).

     2.04  Brokers.  Neither  SteriLogic  nor any  Shareholder  has employed any
broker, agent, or finder in connection with any transaction contemplated by this
Agreement for which MedSolutions,  the Merger Sub, or the Surviving  Corporation
may be liable or responsible to pay.

     2.05 Capitalization.  The capitalization of SteriLogic immediately prior to
the Closing consists of the following:

     (a) Common Stock. A total of 10,000  authorized shares of SteriLogic Common
Stock, of which 5,000 shares are issued and outstanding.

     (b) Options,  Warrants,  Etc. There are no outstanding  options,  warrants,
rights  (including  conversion  or  preemptive  rights)  or  agreements  for the
purchase or  acquisition  from  SteriLogic of any shares of its capital stock or
any securities  convertible  into or ultimately  exchangeable or exercisable for
any shares of capital stock of SteriLogic. No shares of SteriLogic's outstanding
capital  stock are  subject  to any rights of first  refusal or other  rights to
purchase such stock (whether in favor of the SteriLogic or any other Person).

     (c)  Valid  Issuance.  The  outstanding  shares  of the  capital  stock  of
SteriLogic are duly authorized and validly issued, fully paid and nonassessable,
and have been approved by all requisite  shareholder and board action. The offer
and sale by SteriLogic of all capital  stock,  convertible  securities,  rights,
warrants,  or options of SteriLogic issued prior to the Closing was conducted in
material  compliance with all applicable  federal and state securities laws, and
to the Knowledge of SteriLogic  and each of the  Shareholders,  no holder of any
such  securities  has a right of  rescission or has made or threatened to make a
claim for rescission or damages with respect thereto.

     2.06 No  Undisclosed  Liabilities.  Except as  disclosed on any schedule to
this agreement or on Schedule 2.06, there are no liabilities,  liens, mortgages,
encumbrances,  and  imperfections of title to which SteriLogic or its assets are
subject or for which SteriLogic or the Surviving  Corporation may be responsible
(the  "Disclosed  Encumbrances").  Except  for the  Disclosed  Encumbrances  and
express  liabilities  arising under the  contracts  set forth on Schedule  2.22,
there  are  no  liabilities  or  obligations  of  SteriLogic,  whether  accrued,
absolute,  contingent,  or otherwise,  that have affected or could affect in any
way SteriLogic's  assets,  or any of them. Except as set forth on Schedule 2.06,
there is no basis for the  assertion  against  SteriLogic  of any  liability  or
obligation  of any  nature  whatsoever  that  could  result in the  creation  or
imposition  of  any  security  interest,   lien,  charge,  or  encumbrance  upon
SteriLogic's assets.

     2.07  Title  to  the  Assets;   Encumbrances.   Except  for  the  Disclosed
Encumbrances,  SteriLogic has good and  marketable  title to its assets free and
clear of all liens, mortgages,  claims, easements,  pledges, security interests,
or other imperfections of title.

     2.08 Environmental Compliance.

                                       9
<PAGE>

     (a) With respect to SteriLogic's  assets and any other Property (as defined
in Article X of this Agreement)  owned or operated by SteriLogic,  SteriLogic is
in compliance with all applicable Environmental Laws (as defined in Article X of
this  Agreement)  and  has  obtained  and is in  compliance  with  all  permits,
licenses,  and other authorizations  required under any Environmental Law. There
is no past or  present  event,  condition  or  circumstance  that is  likely  to
interfere  with  the  utilization  of  SteriLogic's   assets  by  the  Surviving
Corporation (provided such assets are utilized in a manner consistent with their
use prior to the Effective Time)  constituting a violation of Environmental Laws
or resulting from any failure to comply therewith;

     (b)  SteriLogic  does  not  now and has not  leased,  operated,  owned,  or
exercised  managerial  functions at any facilities or real property with respect
to which such facility or real property is subject to any Proceeding (as defined
in Article X of this Agreement) under any  Environmental  Law, and SteriLogic is
not  aware  of any  facts  or  circumstances  that  could  give  rise  to such a
Proceeding;

     (c) There are no actions or Proceedings pending or, to SteriLogic's or each
of the  Shareholders'  Knowledge  (as  defined in Article X of this  Agreement),
threatened  against  SteriLogic under any Environmental  Law, and SteriLogic has
not received any notice  (whether from any regulatory body or private person) of
any violation, or potential or threatened violation, of any Environmental Law;

     (d) There are no actions or Proceedings pending or, to SteriLogic's or each
of the Shareholders' Knowledge, threatened under any Environmental Law involving
the  release or threat of release of any  Polluting  Substances  (as  defined in
Article X of this Agreement) at or on (i) any Property  currently or in the past
owned,  operated  or leased by  SteriLogic  or over which  SteriLogic  exercised
managerial  functions,  or  (ii)  at any  Property  where  Polluting  Substances
generated by SteriLogic have been disposed;

     (e) Except as set forth on Schedule  2.08,  there is no Property  for which
SteriLogic is or was required to obtain any permit under an Environmental Law to
construct,  demolish,  renovate,  occupy,  operate,  or use such Property or any
portion of it;

     (f) SteriLogic has not generated any Polluting Substances;

     (g) There has been no release of  Polluting  Substances  by  SteriLogic  in
violation of any Environmental Law that would require any report or notification
to any governmental or regulatory authority in or on any Property;

     (h)  SteriLogic  is not under  investigation  or subject to pending  or, to
SteriLogic's or each of the Shareholders'  Knowledge,  threatened  litigation by
federal,  state,  or local  officials  or a private  litigant as a result of any
previous  on-site  management,  treatment,  storage,  release,  or  disposal  of
Polluting Substances or exposure to any Polluting Substances;

                                       10
<PAGE>

     (i) There are no  underground or above ground storage tanks on or under any
Property that are not in conformity with any Environmental Law, and any Property
previously  containing  such tanks has been  remediated in  compliance  with all
Environmental Laws; and

     (j) There is no asbestos-containing material on any Property of SteriLogic.

     2.09 Financial Statements. Attached as Schedule 2.09 are true, correct, and
complete copies of the following financial statements for SteriLogic:  unaudited
balance sheets, statements of income, and statements of cash flows as of and for
the years ended  December 31,  2003,  2004 and 2005,  and an  unaudited  balance
sheet,  statement of income,  and  statement of cash flows as of and for the six
months   ended  June  30,  2006   (collectively,   the   "SteriLogic   Financial
Statements").   The   SteriLogic   Financial   Statements   have  been  prepared
consistently  during the periods  indicated,  are  correct  and  complete in all
respects,  accurately present the financial  condition and results of operations
of  SteriLogic  as of the dates set forth,  and have been prepared in accordance
with generally accepted accounting principles,  consistently applied.  Except as
set  forth  on  Schedule  2.09,  Since  the  date  of the  SteriLogic  Financial
Statements,  there  has  not  been  any  change  in  the  business,  operations,
prospects,  assets,  results of operations or condition  (financial or other) of
SteriLogic,  and no event has occurred or circumstance exists that may result in
such a change.

     2.10  Changes.  Except as set forth on Schedule  2.10,  since June 30, 2006
(the date of most recent financial  statements provided to MedSolutions),  there
has not been:

     (a) any change in the assets, liabilities, financial condition or operating
results  of  SteriLogic   from  that  reflected  in  the  SteriLogic   Financial
Statements,  except changes in the ordinary  course of business,  that has had a
Material Adverse Effect (as defined below);

     (b) any  damage,  destruction  or  loss  to any  assets  or  properties  of
SteriLogic, whether or not covered by insurance, that has had a Material Adverse
Effect;

     (c) any waiver by SteriLogic of a valuable right or of a material debt owed
to it;

     (d) any change or amendment to an agreement by which  SteriLogic  or any of
its assets or  properties  is bound or subject  that has had a Material  Adverse
Effect;

     (e) any loans made by  SteriLogic  to or for the benefit of its  employees,
officers or directors,  or any members of their immediate  families,  other than
travel advances and other advances made in the ordinary course of its business;

     (f) any resignation or termination of any executive officer or key employee
of SteriLogic;

     (g) any material change in any  compensation  arrangement or agreement with
any employee, director or shareholder of SteriLogic;

                                       11
<PAGE>

     (h) any sale,  assignment or transfer of any Intellectual Property or other
intangible assets of SteriLogic;

     (i) any  satisfaction  or discharge of any lien,  claim,  or encumbrance or
payment  of any  obligation  by  SteriLogic,  except in the  ordinary  course of
business  and that is not  material to the  business,  properties  or  financial
condition of SteriLogic;

     (j) any  declaration,  setting  aside or payment or other  distribution  in
respect  of  any of  SteriLogic's  capital  stock,  or any  direct  or  indirect
redemption, purchase or other acquisition of any of such stock by SteriLogic;

     (k) any  mortgage,  pledge,  transfer of a security  interest  in, or lien,
created by SteriLogic, with respect to any of its material properties or assets,
except liens for taxes not yet due or payable;

     (l) any receipt of notice that there has been a loss of, or material  order
cancellation by, any major customer of SteriLogic;

     (m) any other event or condition of any  character  that has had a Material
Adverse Effect; or

     (n) any  agreement  or  commitment  by  SteriLogic  to do any of the things
described in this Section 2.10.

     2.11 Intellectual Property.

     (a) Except as set forth in  Schedule  2.11(a),  SteriLogic  is the owner of
all,  or has the  license  or  right  to  use,  sell  and  license  all of,  the
Copyrights,  Patents, Trade Secrets, Trademarks,  Software and other proprietary
rights (collectively,  "Intellectual Property") that are used in connection with
its business as presently  conducted as of the Effective  Time. For the purposes
of this  Agreement,  "Copyrights"  means any foreign or United States  copyright
registrations and applications for registration  thereof, and any non-registered
copyrights;  "Patents"  means any  foreign or United  States  patents and patent
applications,  including any  divisions,  continuations,  continuations-in-part,
substitutions  or  reissues  thereof,  whether or not patents are issued on such
applications  and whether or not such  applications  are modified,  withdrawn or
resubmitted;   "Trade  Secrets"  means  any  trade  secrets,  research  records,
processes,  procedures,  manufacturing formulae, technical know-how, technology,
blue prints,  designs, plans, inventions (whether patentable and whether reduced
to practice), invention disclosures and improvements thereto; "Trademarks" means
any foreign or United  States  trademarks,  service  marks,  trade dress,  trade
names,  brand  names,  designs and logos,  corporate  names,  product or service
identifiers,  whether  registered or  unregistered,  and all  registrations  and
applications  for  registration  thereof;  and  "Software"  means  any  computer
software programs, source code, object code, data and documentation.

                                       12
<PAGE>

     (b)  Except  as set forth in  Schedule  2.11(b),  none of the  Intellectual
Property  owned by SteriLogic is subject to any  outstanding  judgment,  decree,
order,  writ,  injunction,  regulation,  or rule of any  court  or  governmental
authority,  and no action, suit,  proceeding,  hearing,  investigation,  charge,
complaint,  claim or  demand  is  pending  or,  to  SteriLogic's  or each of the
Shareholders'   Knowledge,    threatened,   which   challenges   the   validity,
enforceability, use or ownership of SteriLogic's Intellectual Property.

     2.12 Financial Institution Accounts; Powers of Attorney. Schedule 2.12 sets
forth (i) the name of each financial  institution in which SteriLogic  maintains
an account or safe deposit box and the names of all persons  authorized  to draw
thereon or to have access  thereto,  and (ii) the names of all persons,  if any,
holding powers of attorney from SteriLogic and a summary  statement of the terms
thereof.

     2.13 Taxes.

     (a) Except as set forth on Schedule  2.13,  SteriLogic has (i) timely filed
all  returns  required  to be filed by it with  respect to all  federal,  state,
local, and foreign income,  payroll,  withholding,  unemployment,  excise, added
value,  social  security,  sales and use,  real and personal  property,  use and
occupancy, business and occupation,  mercantile, real estate, capital stock, and
franchise or other tax (including  interest and penalties  thereon and including
estimated taxes thereof) (hereinafter referred to collectively as "Taxes"); (ii)
paid all Taxes shown to have become due pursuant to such returns; and (iii) paid
all other Taxes for which a notice of  assessment or demand for payment has been
received;

     (b) All  returns for Taxes  filed by or on behalf of  SteriLogic  have been
prepared in accordance with all applicable laws and  requirements and accurately
reflect the taxable  income (or other  measure of Tax) of the entity  filing the
return; and

     (c) There are no Tax liens upon any of SteriLogic's  assets, and SteriLogic
is not  aware of any  audit  or other  proceeding  or  investigation,  or of any
position taken on a Tax return of SteriLogic, that could give rise to a Tax lien
upon any of SteriLogic's assets. SteriLogic has previously provided MedSolutions
with complete,  true, and correct copies of all of  SteriLogic's  federal income
tax returns.

     2.14  Intangible  Assets.  SteriLogic  owns  and  possesses  all  necessary
certificates, permits, authorizations, licenses (collectively,  "Licenses") that
are  required  by the nature of  SteriLogic's  business as  conducted  as of the
Effective Time.

     2.15  Litigation.  Except  as set  forth on  Schedule  2.15,  there  are no
Proceedings  (as defined in Article X of this  Agreement) in progress,  pending,
or, to SteriLogic's or each of the Shareholders'  Knowledge,  threatened against
or affecting SteriLogic,  its assets, or the transactions contemplated hereby in
any  court or  before  any  arbitration  panel of any kind or  before  or by any
Governmental  Authority  (as  defined  in Article X of this  Agreement),  nor to
SteriLogic's or each of the  Shareholders'  Knowledge,  is there any valid basis
for any such arbitration,  claim, action, proceeding,  inquiry or investigation,

                                       13
<PAGE>

which would have a material  adverse affect on the business of SteriLogic or the
Merger Sub as such business is conducted as of the Effective Time.

     2.16 Consents. Except as set forth on Schedule 2.16 and the consents of the
Board of  Directors  and  shareholders  of  SteriLogic,  no  consent,  approval,
license, permit, authorization, or order of any Person is required in connection
with  the  execution  and  delivery  of  this  Agreement  by  SteriLogic  or the
consummation of the transactions contemplated hereby by SteriLogic.

     2.17  Permits,   Licenses,   Etc.   SteriLogic   has  received  no  written
notification  of any  threatened  suspension  or  cancellation  of  any  permit,
license, franchise, order, certificate,  consent,  authorization, or approval of
any  Governmental  Authority  or  administrative  authority  required  to permit
SteriLogic to conduct its business as conducted as of the Effective Time.

     2.18 Absence of Unethical  Business  Practices.  Neither SteriLogic nor any
officer, employee or agent thereof has directly or indirectly given or agreed to
give any gift or  similar  benefit  to any  customer,  contractor,  Governmental
Authority,  or any  employee,  agent,  broker  or  affiliate  of such  Person or
Governmental  Authority  who was or is in a possible  position to help or hinder
SteriLogic, which gift or benefit (a) would subject SteriLogic to any damages or
penalties  in any civil or  criminal  proceeding,  or (b) would  have a Material
Adverse  Effect (as defined in Article X of this  Agreement)  on  SteriLogic  if
discontinued.

     2.19 Books and Records. The books of account and other financial records of
SteriLogic, all of which have been made available to MedSolutions,  are complete
and correct in all material respects.  The minute books of SteriLogic which have
been made available to MedSolutions do not contain accurate and complete records
of all meetings held of, and  corporate  action taken by the Board of Directors,
committees of the Board of Directors and the  shareholders  of  SteriLogic.  All
actions taken by the Board of Directors of  SteriLogic,  any  committees of such
Board of Directors,  and any officers of SteriLogic  prior to the Effective Time
have been ratified by the Board of Directors and the shareholders of SteriLogic.

     2.20 Condition of Assets; Inventory.

     (a)  Each of  SteriLogic's  material  assets  is in good  repair  and  good
operating  condition,  is  suitable  for  immediate  use,  provided  such use is
consistent  with the  manner  in which  such  assets  are  being  used as of the
Effective Date. To SteriLogic's and each of the Shareholders' Knowledge, each of
SteriLogic's material assets is free from latent and patent defects, and, except
with respect to SteriLogic's sharps container system and the respective mounting
hardware (which requires replacement as described in Section 1.08(e) above) none
of such material assets are in need of repair or replacement. All assets used in
SteriLogic's business are in the possession of SteriLogic.

     (b) All of SteriLogic's  inventory is merchantable and fit for the purposes
for which it was procured or manufactured.

                                       14
<PAGE>

     2.21  Certain  Properties.  Schedule  2.21 sets  forth all of the  personal
property and real estate leased to SteriLogic and specifies, in the case of real
estate, the location of each property, the use of the facility thereon, the name
of the owner or the names of the lessor and the  lessee,  the square  footage of
improvements  and the acreage of land if raw property.  SteriLogic has delivered
to MedSolutions a copy of each lease by which  SteriLogic  acquired its interest
in the real estate and  personal  property  described in Schedule  2.21,  all of
which  documents are true and complete  copies  thereof as in effect on the date
hereof.

     2.22  Contracts;  No  Defaults.  Schedule  2.22  contains an  accurate  and
complete  list,  and  SteriLogic  has  delivered  to  MedSolutions  accurate and
complete copies of each written  contract and written  amendment,  supplement or
modification  in respect to any such  contract,  and an  accurate  and  complete
description  of the material  terms of each oral  contract  and oral  amendment,
supplement or modification in respect to any oral or written  contract,  in each
such case to which SteriLogic is a party (collectively, the "Contracts"). Except
as otherwise  set forth on Schedule  2.22,  and except as limited by  applicable
bankruptcy, insolvency,  reorganization,  moratorium, and similar laws affecting
the  enforcement of creditors'  rights  generally and the application of general
principles of equity and judicial discretion, each Contract is in full force and
effect and is valid and  enforceable  in  accordance  with its terms,  is not in
default nor has any event  occurred  which with the passage of time would result
in a default,  and does not require the consent or approval of any party thereto
with respect to the transactions contemplated by this Agreement.

     2.23 Employees.  There are no strike,  labor dispute or union  organization
activities pending or threatened  between SteriLogic and its employees.  None of
SteriLogic's  employees  belongs  to any union or  collective  bargaining  unit.
Except as set forth on Schedule  2.23,  SteriLogic is not a party to or bound by
any currently effective employment contract,  deferred  compensation  agreement,
bonus plan,  incentive plan, stock option plan, profit sharing plan,  retirement
agreement,  or other employee compensation agreement. To SteriLogic's or each of
the Shareholders' Knowledge, no officer or key employee intends to terminate his
or her employment with SteriLogic,  nor does SteriLogic have a present intention
to terminate the employment of any officer or key employee.  Except as set forth
on Schedule 2.23, subject to general principles related to wrongful  termination
of  employees,  the  employment  of each officer and employee of  SteriLogic  is
terminable at the will of SteriLogic.

     2.24 Employee  Benefits.  SteriLogic has no Employee Benefit Plans that are
required to comply with ERISA. For purposes of this Agreement, "Employee Benefit
Plan" means any "employee  pension  benefit plan" (as defined in Section 3(2) of
ERISA),  any  "employee  welfare  benefit  plan" (as defined in Section  3(1) of
ERISA), and any other written or oral plan,  agreement or arrangement  involving
direct  or  indirect  compensation,   including  insurance  coverage,  severance
benefits,  disability benefits,  deferred compensation,  bonuses, stock options,
stock purchase,  phantom stock,  stock  appreciation or other forms of incentive
compensation or  post-retirement  compensation.  For purposes of this Agreement,
"ERISA" means the Employee Retirement Income Security Act of 1974, as amended.

     2.25 Insurance.  Schedule 2.25 lists each insurance policy (including fire,
theft,   casualty,   general   liability,    professional   liability,   workers
compensation,  business  interruption,   environmental,  product  liability  and

                                       15
<PAGE>

automobile  insurance  policies  and  bond  and  surety  arrangements)  to which
SteriLogic is a party.  There is no material claim pending under any such policy
as to which coverage has been questioned,  denied or disputed by the underwriter
of such policy.  All premiums due and payable  under all such policies have been
paid, SteriLogic is not liable for any retroactive premiums or similar payments,
and  SteriLogic  is otherwise in  compliance  in all material  respects with the
terms of such policies  applicable to it. Neither SteriLogic nor any Shareholder
has any Knowledge of any threatened termination of, or material premium increase
(other than increases that are consistent with the increases  experienced by the
industry in which SteriLogic does business) with respect to, any such policy.

     2.26 Obligations to Related  Parties.  No employee,  officer,  director or,
shareholder  of SteriLogic or member of his or her immediate  family is indebted
to SteriLogic,  nor is SteriLogic indebted (or committed to make loans or extend
or  guarantee  credit) to any of them  other than (i) for  payment of salary for
services rendered, (ii) reimbursement for reasonable expenses incurred on behalf
of SteriLogic  and (iii) for other  standard  employee  benefits made  generally
available to all employees (including stock option agreements  outstanding under
any stock option plan  approved by  SteriLogic's  Board of  Directors  and stock
purchase agreements  approved by SteriLogic's Board of Directors).  None of such
persons has any direct or indirect ownership interest in any firm or corporation
with which  SteriLogic  is affiliated  or with which  SteriLogic  has a business
relationship,  or any firm or corporation that competes with SteriLogic,  except
in  connection  with the  ownership of stock in publicly  traded  companies.  No
employee,  officer,  director or shareholder  of  SteriLogic,  nor any member of
their immediate families, is, directly or indirectly, interested in any material
Contract  with  SteriLogic  (other  than  such  contracts  as relate to any such
person's  ownership of capital  stock or other  securities of SteriLogic or such
person's employment agreement with SteriLogic).

     2.27 Accounts  Receivable.  The accounts receivable shown on the SteriLogic
Financial Statements and the accounts receivable of SteriLogic arising after the
date of the  SteriLogic  Financial  Statements  and prior to the Effective  Time
arose from bona fide  transactions  in the ordinary  course of business and have
been collected or will be collectible in the book amounts thereof.  None of such
accounts   receivable  is  subject  to  any  claim  of  offset,   recoupment  or
counterclaim,  and neither  SteriLogic nor any  Shareholder has any Knowledge of
any  specific  facts  that  would be likely to give rise to any such  claim.  No
amount  of such  accounts  receivable  is  contingent  upon the  performance  by
SteriLogic of any  obligation  and no agreement for deduction or discount or any
type of credit has been made with respect to any such  accounts  receivable.  No
customer of the Company has proposed  any discount or reduction  with respect to
such customer's accounts receivable.

     2.28 Representations Regarding the Acquisition of the Merger Shares.

     (a)  Acquire  Entirely  for  Own  Account.  This  Agreement  is  made  with
SteriLogic  and the  Shareholders  in reliance  upon Abele's  representation  to
MedSolutions that the Merger Shares to be received by Abele will be acquired for
investment  for Abele's own account,  not as a nominee or agent,  and not with a
view to the resale or  distribution  of any part thereof,  and that Abele has no
present  intention  of selling or granting  any  participation  in or  otherwise
distributing  the  same.  Abele  further  represents  that it does  not have any

                                       16
<PAGE>

contract,  undertaking,  agreement  or  arrangement  with  any  Person  to sell,
transfer  or grant  participations  to such  Person or to any third  Person with
respect to the Merger Shares.

     (b)  Sophistication;  Accredited  Investor  Status.  Abele is a Person  who
either alone or with its purchaser  representative(s)  has sufficient  knowledge
and experience in financial and business matters to be capable of evaluating the
merits and risks of an investment in MedSolutions.

     (c) Speculative  Investment.  Abele understands the speculative  nature and
risks of investments  associated with  MedSolutions and confirms that it is able
to bear the risk of the investment,  and that there may not be any public market
for the Merger Shares received hereby.

     (d) No Coercion or  Solicitation.  Abele has freely  entered this Agreement
and has been subject to neither pressure to make a hasty or uninformed  decision
to enter into this Agreement nor solicitation to receive the Merger Shares.

     (e) Transfer  Restrictions.  Abele hereby acknowledges that MedSolutions is
not under any  obligation  to  register or seek an  exemption  under any federal
and/or state  securities  laws for any sale or transfer of the Merger  Shares by
Abele, and Abele hereby further  acknowledges  that the Merger Shares constitute
restricted  securities as that term is defined in Rule 144 under the  Securities
Act and  that  the  Merger  Shares  may not be sold,  transferred,  assigned  or
hypothecated  unless  there is an  effective  registration  statement  under the
Securities Act covering the Merger Shares,  the sale is made in accordance  with
Rule 144 under the  Securities  Act,  or  MedSolutions  receives  an  opinion of
counsel of Abele  reasonably  satisfactory  to  MedSolutions,  stating that such
sale, transfer,  assignment or hypothecation is exempt from the registration and
prospectus delivery requirements of the Securities Act.

     (f) Disclosure of Information.  Abele has received all the information that
it considers necessary or appropriate for deciding whether to acquire the Merger
Shares.  Abele  further  represents  that  it has  had  the  opportunity  to ask
questions of MedSolutions and receive answers from  MedSolutions,  to the extent
that  MedSolutions  possessed  such  information  or could  acquire  it  without
unreasonable  effort or expense,  necessary  to evaluate the merits and risks of
any investment in MedSolutions.  Further, Abele has been given an opportunity to
question the appropriate executive officers of MedSolutions.

     (g) Lock-up  Agreement.  Abele  hereby  acknowledges  that the  shareholder
lock-up  agreement  with respect to the Merger Shares between  MedSolutions  and
Abele in the form  attached  hereto as Exhibit D shall follow the Merger  Shares
upon the sale, transfer, assignment or hypothecation of any or all of the Merger
Shares to any transferee of Abele.

                                       17
<PAGE>

     (h) Legends.  It is understood that the certificates  evidencing the Merger
Shares will bear the legend set forth below:

     "THE  SECURITIES  REPRESENTED  HEREBY  HAVE NOT BEEN  REGISTERED  UNDER THE
     SECURITIES  ACT OF 1933,  AS AMENDED (THE "ACT"),  OR UNDER THE  SECURITIES
     LAWS  OF  ANY  OTHER   JURISDICTIONS.   THESE  SECURITIES  ARE  SUBJECT  TO
     RESTRICTIONS  ON  TRANSFERABILITY  AND RESALE AND MAY NOT BE TRANSFERRED OR
     RESOLD  EXCEPT  AS  PERMITTED  UNDER  THE  ACT  AND  THE  APPLICABLE  STATE
     SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS
     SHOULD BE AWARE THAT THEY MAY BE  REQUIRED TO BEAR THE  FINANCIAL  RISKS OF
     THIS  INVESTMENT  FOR AN  INDEFINITE  PERIOD OF TIME.  THE  ISSUER OF THESE
     SECURITIES  MAY  REQUIRE  AN  OPINION  OF  COUNSEL  IN FORM  AND  SUBSTANCE
     SATISFACTORY  TO THE ISSUER TO THE EFFECT  THAT ANY  PROPOSED  TRANSFER  OR
     RESALE IS IN COMPLIANCE  WITH THE ACT AND ANY APPLICABLE  STATE  SECURITIES
     LAWS.

     THE  SECURITIES  REPRESENTED  HEREBY ARE SUBJECT TO A  SHAREHOLDER  LOCK-UP
     AGREEMENT  THAT  PLACES  CERTAIN  RESTRICTIONS  UPON  THE  SALE,  TRANSFER,
     ASSIGNMENT OR HYPOTHECATION OF ANY OR ALL OF SUCH SHARES. SUCH RESTRICTIONS
     SHALL  FOLLOW  THE  SHARES  REPRESENTED  HEREBY  UPON THE  SALE,  TRANSFER,
     ASSIGNMENT OR  HYPOTHECATION OF ANY OR ALL OF SUCH SHARES TO ANY TRANSFEREE
     BY THE HOLDER HEREOF. A COPY OF THE FORM OF SHAREHOLDER  LOCK-UP  AGREEMENT
     MAY BE OBTAINED  FROM THE ISSUER UPON WRITTEN  REQUEST  THEREFOR  MAILED OR
     DELIVERED TO THE FOLLOWING ADDRESS: MEDSOLUTIONS,  INC., 12750 MERIT DRIVE,
     PARK CENTRAL VII, SUITE 770, DALLAS, TEXAS 75251, ATTN: SECRETARY."

The legend set forth above shall be removed by MedSolutions from any certificate
evidencing Merger Shares upon delivery to MedSolutions of an opinion by counsel,
reasonably satisfactory to MedSolutions, that a registration statement under the
Securities  Act is at that time in effect with respect to the legended  security
or that such security can be freely  transferred in a public sale without such a
registration  statement  being  in  effect  and  that  such  transfer  will  not
jeopardize  the  exemption or  exemptions  from  registration  pursuant to which
MedSolutions issued the Merger Shares.

     2.29 Full Disclosure. No representation or warranty regarding SteriLogic or
any Shareholder  made in this Agreement,  the Exhibits and Disclosure  Schedules
hereto,  or the documents to be delivered by SteriLogic and the  Shareholders at
the Closing, contains any untrue statement of a material fact, or omits to state
a material fact  necessary to make the statements or facts  contained  herein or
therein not misleading.  Each of the Exhibits and Disclosure  Schedules attached

                                       18
<PAGE>

hereto is a true and complete list or description,  as appropriate, of the items
purported to be listed or described thereon.

                                   ARTICLE III

                 REPRESENTATIONS AND WARRANTIES OF MEDSOLUTIONS
                               AND THE MERGER SUB

     To induce  SteriLogic and the Shareholders to enter into this Agreement and
to consummate the transactions contemplated hereby,  MedSolutions and the Merger
Sub  jointly  and  severally   represent  and  warrant  to  SteriLogic  and  the
Shareholders as follows:

     3.01  Organization  and Good Standing.  Each of MedSolutions and the Merger
Sub is a corporation  duly  organized,  validly  existing,  and in good standing
under the laws of the State of Texas.  Exhibits 3.1 through 3.6,  inclusive,  to
MedSolutions' Form 10-KSB for the fiscal year ended December 31, 2005 (the "Form
10-KSB") are true and complete copies of MedSolutions' Articles of Incorporation
and all  amendments  thereto.  Exhibit  3.7 to the  Form  10-KSB  is a true  and
complete  copy of the bylaws of  MedSolutions  as presently in effect.  Schedule
3.01  includes (i) a true and complete copy of the Merger Sub's  Certificate  of
Formation,  certified by the Texas Secretary of State;  (ii) a true and complete
copy of the Bylaws of the Merger Sub presently in effect,  certified as true and
correct by the Merger Sub's  Secretary;  and (iii) true and  complete  copies of
certificates  of existence and account status for each of  MedSolutions  and the
Merger  Sub,  certified  by the  Secretary  of  State  of  Texas  and the  Texas
Comptroller of Public Accounts, respectively, as of the Effective Time.

     3.02  Authority.   MedSolutions  has  all  requisite  corporate  power  and
authority to execute and deliver this  Agreement  and the Note and to consummate
the  transactions  contemplated  hereby  and  thereby.  The  Merger  Sub has all
requisite  corporate  power and authority to execute and deliver this  Agreement
and the Merger  Certificate  and to  consummate  the  transactions  contemplated
hereby  and  thereby.  This  Agreement  and the Note have been  approved  by the
MedSolutions'  Board of Directors and have been duly authorized,  executed,  and
delivered by MedSolutions.  This Agreement and the Merger  Certificate have been
approved by the Merger Sub's Board of Directors  and have been duly  authorized,
executed,  and delivered by the Merger Sub. No other corporate act or proceeding
on the part of either  MedSolutions  or the Merger Sub is necessary to authorize
this  Agreement,  the  Note  or  the  Merger  Certificate   (collectively,   the
"Transaction Documents"), as applicable, or the transactions contemplated hereby
or thereby. The Transaction Documents have been duly authorized,  executed,  and
delivered  by each of  MedSolutions  and the  Merger  Sub,  as  applicable,  and
constitute a valid and binding obligation of each of MedSolutions and the Merger
Sub, as  applicable,  enforceable  against such party in  accordance  with their
terms, except as limited by applicable bankruptcy,  insolvency,  reorganization,
moratorium,  and similar laws  affecting the  enforcement  of creditors'  rights
generally  and the  application  of general  principles  of equity and  judicial
discretion.  MedSolutions  has delivered to SteriLogic a copy of the resolutions
of  MedSolutions'  Board  of  Directors,   certified  as  true  and  correct  by
MedSolutions'  Secretary,  approving this Agreement,  the issuance of the Merger
Shares  and the Note,  and  authorizing  the  execution  hereof  and  thereof by
MedSolutions'  President.  The Merger Sub has  delivered to SteriLogic a copy of

                                       19
<PAGE>

the  resolutions  of the Merger Sub's Board of Directors,  certified as true and
correct by the Merger Sub's Secretary,  approving this Agreement and authorizing
the execution hereof and thereof by the Merger Sub's President.

     3.03 No Violation.  Neither the execution and delivery by  MedSolutions  of
the  Transaction   Documents  nor  the   consummation  by  MedSolutions  of  the
transactions  contemplated  thereby will (i) violate any  provision of the Texas
Business Corporation Act, the Articles of Incorporation of MedSolutions,  or the
Bylaws of  MedSolutions;  (ii) violate,  or be in conflict with, or constitute a
default (or an event or condition  that,  with notice or lapse of time, or both,
would  constitute  a  default)  under,  or  result  in the  termination  of,  or
accelerate  the  performance  required  by,  or cause  the  acceleration  of the
maturity of any  agreement to which  MedSolutions  is subject,  or result in the
creation  or  imposition  of any  security  interest,  lien,  charge,  or  other
encumbrance  upon any of MedSolutions'  assets under, any note, bond,  mortgage,
indenture, deed of trust, license, lease, contract,  commitment,  understanding,
arrangement,  agreement,  or  restriction  of any  kind or  character  to  which
MedSolutions is a party or by which  MedSolutions may be bound or affected or to
which any of  MedSolutions'  assets is subject;  or (iii) violate any statute or
law or any judgment, decree, order, writ, injunction, regulation, or rule of any
court or Governmental Authority.

     Neither the  execution  and  delivery by the Merger Sub of the  Transaction
Documents  nor  the   consummation  by  the  Merger  Sub  of  the   transactions
contemplated  thereby  will (i)  violate  any  provision  of the Texas  Business
Organizations  Code,  the  Certificate  of  Formation  of the Merger Sub, or the
Bylaws of the Merger Sub; (ii) violate,  or be in conflict with, or constitute a
default (or an event or condition  that,  with notice or lapse of time, or both,
would  constitute  a  default)  under,  or  result  in the  termination  of,  or
accelerate  the  performance  required  by,  or cause  the  acceleration  of the
maturity of any  agreement to which the Merger Sub is subject,  or result in the
creation  or  imposition  of any  security  interest,  lien,  charge,  or  other
encumbrance upon any of the Merger Sub's assets under, any note, bond, mortgage,
indenture, deed of trust, license, lease, contract,  commitment,  understanding,
arrangement,  agreement,  or  restriction  of any kind or character to which the
Merger Sub is a party or by which the Merger Sub may be bound or  affected or to
which any of the Merger Sub's assets is subject; or (iii) violate any statute or
law or any judgment, decree, order, writ, injunction, regulation, or rule of any
court or Governmental Authority.

     3.04  Brokers.  Neither  MedSolutions  nor the Merger Sub has  employed any
broker, agent, or finder in connection with any transaction contemplated by this
Agreement for which  SteriLogic or the Shareholders may be liable or responsible
to pay.

     3.05  Litigation.  Except as  disclosed  in the Form  10-KSB,  there are no
suits, arbitrations, claims, actions, Proceedings,  investigations, or inquiries
in progress,  pending,  or, to MedSolutions'  Knowledge,  threatened  against or
affecting MedSolutions,  MedSolutions' assets, or the transactions  contemplated
hereby in any court or before any arbitration  panel of any kind or before or by
any  Governmental  Authority,  except  such  Proceedings  which would not have a
Material Adverse Effect.

                                       20
<PAGE>

     3.06 Full Disclosure.  No representation or warranty of MedSolutions or the
Merger Sub made in this  Agreement  contains any untrue  statement of a material
fact that affects the ability of  MedSolutions  to consummate  the  transactions
contemplated  by this  Agreement or omits to state a material fact  necessary to
make the statements or facts contained herein not misleading.

     3.07 Consents. No consent,  approval,  license, permit,  authorization,  or
order of any person is required in connection with the execution and delivery of
Transaction  Documents by MedSolutions or the Merger Sub or the  consummation of
the transactions contemplated hereby by MedSolutions or the Merger Sub.

     3.08  Exemption.  The issuance of the Merger Shares  hereunder to Abele, to
the extent the  representations  and warranties set forth in Section 2.28 hereof
are true, correct and complete in all respects,  is exempt from the registration
requirements  under the Securities  Act of 1933, as amended,  and all applicable
state securities laws.

     3.09  Issuance of Common Stock.  The Merger Shares being issued  hereunder,
when issued in accordance  with this  Agreement,  will have been validly issued,
fully paid and  non-assessable and will be free and clear of any lien, charge or
other  encumbrance  (other than as set forth in this  Agreement) and will not be
subject to any preemptive or similar rights.

                                   ARTICLE IV

                  COVENANTS OF STERILOGIC AND THE SHAREHOLDERS

     4.01  Covenants  of  SteriLogic.  During the  period  from the date of this
Agreement and continuing until the Effective Time,  SteriLogic agrees (except as
expressly  contemplated  or permitted by this  Agreement,  or to the extent that
MedSolutions shall otherwise consent in writing) that:

     (a) Ordinary  Course.  SteriLogic shall carry on its business in the usual,
regular and  ordinary  course in  substantially  the same  manner as  heretofore
conducted;

     (b)  Dividends;  Changes in Stock.  Except as set forth on  Schedule  4.01,
SteriLogic  shall  not  (i)  declare  or pay  any  dividends  on or  make  other
distributions  in respect of any of its capital  stock,  or (ii)  repurchase  or
otherwise  acquire,  or permit any subsidiary to purchase or otherwise  acquire,
any shares of its capital stock.

     (c) Issuance of Securities.  Except as set forth on Schedule 4.01, prior to
Closing hereunder,  SteriLogic shall not issue, deliver or sell, or authorize or
propose the  issuance,  delivery or sale of, any shares of its capital  stock of
any class,  any voting debt or any securities  convertible  into, or any rights,
warrants  or options to acquire,  any such  shares,  voting debt or  convertible
securities;

     (d) Governing Documents. SteriLogic shall not amend or propose to amend its
organizational charter or bylaws;

                                       21
<PAGE>

     (e) No Dispositions.  Except as set forth on Schedule 4.01,  except for the
transfer  of assets in the  ordinary  course of business  consistent  with prior
practice, SteriLogic shall not sell, lease, encumber or otherwise dispose of, or
agree to sell, lease, encumber or otherwise dispose of, any of its assets, which
are material, individually or in the aggregate, to SteriLogic;

     (f) Indebtedness.  SteriLogic shall not incur any indebtedness for borrowed
money or guarantee any such indebtedness or issue or sell any debt securities or
warrants or rights to acquire any debt securities of such party or guarantee any
debt  securities  of others  other than in each case in the  ordinary  course of
business consistent with prior practice;

     (g)  Employee  Compensation.  Except in the  ordinary  course of  business,
SteriLogic shall not grant any severance or termination pay (other than pursuant
to  policies  or  contracts  of  SteriLogic  in  effect on the date  hereof  and
disclosed to MedSolutions in the Disclosure  Schedules  attached  hereto) to, or
enter into or amend any  employment  or  severance  agreement  with,  any of its
directors,  officers  or  employees;  adopt  any new  employee  benefit  plan or
arrangement  of any type; or award any increase in  compensation  or benefits to
its directors, officers or employees;

     (h) Other  Actions.  SteriLogic  shall not take any action that would or is
reasonably  likely to result in any of its  representations  and  warranties set
forth in this  Agreement  being  untrue  as of the date  made (to the  extent so
limited),  or in any of the conditions precedent set forth in Article VII hereof
not being satisfied; or

     (i) Certain  Agreements.  SteriLogic  shall not enter into any agreement or
commitment to contravene any of its obligations set forth in this Section 4.01.

     4.02 No Solicitation.  So long as this Agreement remains in effect, neither
SteriLogic  nor any  Shareholder  shall,  directly or  indirectly,  encourage or
solicit or hold discussions or negotiations with, or provide any information to,
any  person,  entity  or group  (other  than  MedSolutions  or the  Merger  Sub)
concerning  any merger or sale of shares of capital  stock of SteriLogic or sale
of a substantial portion or all of SteriLogic's assets or liabilities outside of
the ordinary course of its business.

     4.03  Approval  of the  Shareholders.  SteriLogic  will (i) take all  steps
necessary  to duly  call,  give  notice  of,  convene  and hold a meeting of its
shareholders (the "Shareholders Meeting"), if and as required by applicable law,
for the purpose of securing such  shareholders'  approval of this  Agreement and
the Merger,  (ii) recommend to its  shareholders  the approval of this Agreement
and the transactions  contemplated  hereby and use their reasonable best efforts
to obtain,  as promptly as practicable,  such approval,  and (iii) cooperate and
consult with MedSolutions with respect to each of the foregoing matters.

     4.04  Oral  Contracts.  The  Shareholders  shall  deliver  or  cause  to be
delivered  to  MedSolutions,  on or  before  the  six-month  anniversary  of the
Effective Time,  executed written contracts (of at least ninety percent (90%) of
all oral contracts) in form and substance reasonably  acceptable to MedSolutions
replacing each oral contract listed on Schedule 2.22.

                                       22
<PAGE>

                                    ARTICLE V

                  SURVIVAL OF REPRESENTATIONS; INDEMNIFICATION.

     5.01 Indemnification of MedSolutions and the Surviving Corporation. Each of
the Shareholders hereby agrees, jointly and severally, to indemnify, defend, and
hold harmless MedSolutions and the Surviving  Corporation,  and their successors
in  interest,  and their  respective  officers,  directors,  employees,  agents,
attorneys, and stockholders (each a "MedSolutions  Indemnitee") from and against
all demands, claims, actions, or causes of action,  assessments,  losses, taxes,
damages,  liabilities,  costs,  and  expenses,  including,  without  limitation,
interest,  penalties,  and reasonable attorneys' fees and expenses (collectively
"Damages"),  asserted  against,  assessed  upon,  resulting to, imposed upon, or
incurred by a MedSolutions Indemnitee by reason of or resulting from a breach of
any representation,  warranty, or a breach or threatened breach of any covenant,
obligation,  or agreement of SteriLogic  or a  Shareholder  contained in or made
pursuant to this  Agreement,  including  the  Disclosure  Schedules and Exhibits
hereto.  In addition,  each  Shareholder  agrees to indemnify  any  MedSolutions
Indemnitee  for  Damages as they are  incurred  by the  MedSolutions  Indemnitee
irrespective  of any ongoing or continuing  legal  proceedings  and the relative
timeframes and issues associated with such proceedings,  or the relative success
or nonsuccess the MedSolutions Indemnitee may experience in such proceedings.

     5.02  Indemnification  of the Shareholders.  MedSolutions  hereby agrees to
indemnify,  defend,  and hold  harmless the  Shareholders,  their  successors in
interest, heirs and assigns, and their respective officers, managers, employees,
agents, attorneys and members (each a "Shareholder Indemnitee") from and against
all Damages  asserted  against,  assessed  upon,  resulting to, imposed upon, or
incurred by a Shareholder  Indemnitee by reason of or resulting from a breach of
any representation or warranty of MedSolutions or the Merger Sub contained in or
made pursuant to this Agreement and the other Transaction  Documents,  including
the Exhibits and  Disclosure  Schedules  thereto and the operation of Merger Sub
after the  Effective  Time.  In addition,  MedSolutions  agrees to indemnify any
Shareholder  Indemnitee  for  Damages as they are  incurred  by the  Shareholder
Indemnitee  irrespective of any ongoing or continuing legal  proceedings and the
relative timeframes and issues associated with such proceedings, or the relative
success  or  nonsuccess  the  Shareholder  Indemnitee  may  experience  in  such
proceedings.

     5.03   Indemnification   Claims   Procedure.    All   claims   subject   to
indemnification  under Section 5.01 or 5.02 above shall be asserted and resolved
in  accordance  with the  following  provisions.  Promptly  after  receipt  by a
MedSolutions Indemnitee or a Shareholder Indemnitee (either is referred to as an
"Indemnitee"  in this Section 5.03) of notice of the  commencement of any action
(including any governmental action), such Indemnitee will, if a claim in respect
thereof is to be made against any indemnifying party (the "Indemnifying  Party")
under this Article V, deliver to the Indemnifying  Party a written notice of the
commencement  thereof  and the  Indemnifying  Party  shall  have  the  right  to
participate in, and, to the extent the  Indemnifying  Party so desires,  jointly
with any other  Indemnifying  Party  similarly  noticed,  to assume the  defense
thereof with counsel mutually  satisfactory to the parties;  provided,  however,
that an Indemnitee  (together with all other Indemnitees that may be represented
without  conflict by one  counsel)  shall have the right to retain one  separate

                                       23
<PAGE>

counsel  at  its  own  cost.  The  failure  to  deliver  written  notice  to the
Indemnifying  Party within a  reasonable  time of the  commencement  of any such
action,  if materially  prejudicial to its ability to defend such action,  shall
relieve such  Indemnifying  Party of any liability to the Indemnitee  under this
Article V to the extent of the prejudice caused by such failure.

     5.04 Expiration of Indemnification  Obligations. All obligations to provide
indemnification  pursuant  to this  Article  V  shall  terminate  on the  second
anniversary of the Closing Date,  other than claims arising from  environmental,
employee  benefit or tax issues,  which shall not terminate until the applicable
statutes of limitations for such claims have expired.

     5.05 Indemnification Threshold. The parties to this Agreement agree that no
Indemnitee will seek indemnification for any and all claims hereunder unless and
until such claim or claims  aggregate to Twenty  Thousand  Dollars  ($20,000.00)
(the "Indemnification Threshold").  After the Indemnification Threshold has been
reached,  such  party  may seek  indemnification  for the  amount of any and all
claims hereunder,  including without  limitation all amounts up to and including
the Indemnification  Threshold. The parties to this Agreement further agree that
the  liability  of each of  MedSolutions  or the  Shareholders  relating  to the
indemnification of Indemnitees hereunder shall not exceed, in the aggregate, One
Million Eight Hundred Thousand Dollars ($1,800,000.00);  provided,  however that
such limitation  shall not apply with respect to claims by MedSolutions  arising
from environmental issues hereunder.

     5.06 Offset Disputes.  In the event that MedSolutions desires to offset the
amount of any claim or claims hereunder against the outstanding principal amount
of the Note,  MedSolutions  shall provide written notice (an "Offset Notice") to
Abele setting forth the amount to be offset and the reason  therefor.  Abele may
dispute  any such offset by  providing  written  notice (a "Dispute  Notice") to
MedSolutions within 10 calendar days of the date of MedSolutions' Offset Notice.
Notwithstanding  any  provision  of this  Agreement to the  contrary,  a Dispute
Notice  shall be  deemed  received  by  MedSolutions  only upon  actual  receipt
thereof.  In the event that  MedSolutions has not received a Dispute Notice from
Abele  within such 10-day  period,  Abele shall be deemed to have  accepted  the
offset described in the Offset Notice. In the event that MedSolutions receives a
Dispute Notice from Abele within such 10-day period,  and MedSolutions and Abele
are not  able to  resolve  such  dispute  within  30 days of the  date on  which
MedSolutions  receives such Dispute Notice,  MedSolutions shall place the amount
which is in dispute into escrow with Park Cities Bank,  Dallas,  Texas  ("Escrow
Agent") at such times and in such  installments as would otherwise be payable to
Abele  pursuant to the terms of the Note, and such amount shall remain in escrow
until  such  time as such  dispute  has been  resolved  in  accordance  with the
Commercial Arbitration Rules of the American Arbitration  Association,  at which
time such escrowed amount shall be disbursed by the Escrow Agent upon receipt of
a joint written  direction from  MedSolutions or Abele to MedSolutions or Abele,
as the case may be, together with any earnings  thereon,  in accordance with the
determination of such arbitration proceedings.

                                       24
<PAGE>

                                   ARTICLE VI

                              ADDITIONAL AGREEMENTS

     6.01 Legal Conditions to Merger.  Each of MedSolutions,  the Merger Sub and
SteriLogic shall take all reasonable  actions  necessary to comply promptly with
all legal requirements which may be imposed on it with respect to the Merger and
will promptly cooperate with and furnish information to each other in connection
with any such requirements imposed upon any of them or upon any of their related
entities or subsidiaries  in connection  with the Merger.  Each party shall take
all reasonable  actions  necessary to obtain (and will cooperate with each other
in obtaining) any consent, authorization, order or approval of, or any exemption
by, any Governmental Entity or other public or private third party,  required to
be  obtained or made by  MedSolutions,  the Merger Sub or  SteriLogic  or any of
their related  entities or  subsidiaries  in  connection  with the Merger or the
taking of any action contemplated thereby or by this Agreement.

     6.02  SteriLogic's  and the Merger Sub's Action.  The Board of Directors of
each of SteriLogic and the Merger Sub has (i) determined that the Merger is fair
and in the best interests of such  corporation and its respective  shareholders,
and (ii) adopted this Agreement in accordance with the applicable  provisions of
the statutes of the States of Pennsylvania and Texas, respectively. The Board of
Directors  of each of  SteriLogic  and the  Merger  Sub has  directed  that this
Agreement and the Merger be submitted to its respective  shareholders  for their
adoption and approval and resolved to recommend  that its  shareholders  vote in
favor of the adoption of this Agreement and the approval of the Merger.

     6.03  Disclosure  Schedules.  A fact or item  disclosed  on any  disclosure
schedule  shall be  considered  disclosed  for  purposes of any other  schedule,
representation or warranty hereto. If any representation,  warranty or statement
of  SteriLogic or any  Shareholder  in this  Agreement or any of the  disclosure
schedules  delivered to  MedSolutions  shall be  incorrect  prior to the Closing
Date, SteriLogic and the Shareholders shall deliver to MedSolutions a supplement
in order that said representation,  warranty,  disclosure schedule or statement,
as so  supplemented,  shall be true and  correct to the extent  provided in this
Agreement.  Except  for  matters  which are  immaterial,  the  delivery  of such
supplement  to  MedSolutions  shall  not in any  manner  constitute  a waiver by
MedSolutions of any of its rights under this Agreement.

     6.04 Certain  Liabilities.  The  Shareholder  shall deliver to MedSolutions
full copies of all  documentation  relating to the liabilities of SteriLogic set
forth on Schedule 2.22 hereto within 15 days of the Effective Time.

                                   ARTICLE VII

                              CONDITIONS PRECEDENT

     7.01  Conditions  to Each  Party's  Obligation  To Effect the  Merger.  The
respective  obligations  of each party to effect the Merger shall be conditioned
upon the  filing  and  obtainment  of all  authorizations,  consents,  orders or
approvals of, or declarations or filings with, or expirations of waiting periods
imposed  by,  any  Governmental  Entity  or by  any  applicable  law,  rule,  or
regulation  governing the transactions  contemplated  hereby,  including without

                                       25
<PAGE>

limitation the approval of the Merger by the holders of not less than a majority
of the issued and outstanding shares of SteriLogic Common Stock.

     7.02  Conditions to  Obligations  of  MedSolutions  and the Merger Sub. The
obligations of MedSolutions  and the Merger Sub to effect the Merger are subject
to the  satisfaction  of the following  conditions on or before the Closing Date
unless waived by MedSolutions and the Merger Sub:

     (a) Representations  and Warranties.  The representations and warranties of
SteriLogic and the  Shareholders  set forth in this Agreement  shall be true and
correct in all material respects as of the date of this Agreement and (except to
the extent such  representations  and warranties speak as of an earlier date) as
of the  Closing  Date as though made on and as of the  Closing  Date,  except as
otherwise contemplated by this Agreement, and MedSolutions shall have received a
certificate  signed on behalf of  SteriLogic  by the  President of SteriLogic to
such effect.

     (b)  Performance  of  Obligations  of  SteriLogic  and  the   Shareholders.
SteriLogic and the  Shareholders  shall have performed in all material  respects
all  obligations  required to be  performed  by them under this  Agreement at or
prior the Closing  Date,  and  MedSolutions  shall have  received a  certificate
signed on behalf of SteriLogic by the President of SteriLogic to such effect.

     (c) Closing Documents.  MedSolutions and the Merger Sub shall have received
such   certificates  and  other  closing   documents  from  SteriLogic  and  the
Shareholders  as counsel for  MedSolutions  and the Merger Sub shall  reasonably
request.

     (d)  Consents.  SteriLogic  shall have  obtained the consent or approval of
each person whose consent or approval  shall be required in connection  with the
transactions  contemplated  hereby  under  any loan or credit  agreement,  note,
mortgage,  indenture,  lease or other agreement or instrument,  except those for
which failure to obtain such consents and approvals would not, in the reasonable
opinion of  MedSolutions  or the Merger Sub,  individually  or in the aggregate,
have a material  adverse  effect on the Surviving  Corporation  taken as a whole
upon the consummation of the transactions  contemplated hereby. SteriLogic shall
also have received the approval of its  shareholders  with respect to the Merger
in accordance with applicable law.

     (e) Due  Diligence  Review.  MedSolutions  and the  Merger  Sub shall  have
completed to their reasonable satisfaction a review of the business, operations,
finances,  assets and  liabilities of SteriLogic  and shall not have  determined
that any of the  representations  or warranties of SteriLogic or any Shareholder
contained  herein are, as of the date hereof or the Closing Date,  inaccurate in
any  material  respect or that  SteriLogic  or any  Shareholder  is otherwise in
violation of any of the provisions of this Agreement.

     (f)  Pending  Litigation.  There  shall  not be  any  litigation  or  other
proceeding  pending or  threatened to restrain or  invalidate  the  transactions
contemplated  by this  Agreement,  which,  in the sole  reasonable  judgment  of
MedSolutions or the Merger Sub, made in good faith,  would make the consummation

                                       26
<PAGE>

of the Merger imprudent. In addition, there shall not be any other litigation or
other proceeding pending or threatened against  SteriLogic,  the consequences of
which,  in the  sole  judgment  of  MedSolutions  or the  Merger  Sub,  could be
materially adverse to the Surviving Corporation.

     (g)  Non-Competition  and  Non-Solicitation  Agreements.  Each  of  William
Christopher  Kerr and  Christopher S. Abele shall have executed and delivered to
MedSolutions  a  non-competition  and  non-solicitation  agreement  in the  form
attached hereto as Exhibit E.

     (h) Consulting  Agreement.  Consular,  LLC, a limited  liability company of
which  William  Christopher  Kerr is the sole  member,  shall have  executed and
delivered to MedSolutions a consulting  agreement in the form attached hereto as
Exhibit F (the "Consulting Agreement").

     (i)  Transfer  of Certain  Assets and  Liabilities.  SteriLogic  shall have
transferred,  to the sole and absolute satisfaction of MedSolutions,  all of its
outstanding  liabilities other than those liabilities set forth on Schedule 2.06
attached hereto and its Maine operating  division into Oxus  Environmental,  LLC
("Oxus"),  such that after such transfer  SteriLogic  shall only have the assets
and  liabilities  reflected  on the balance  sheet  attached  hereto as Schedule
7.02(i).

     (j) Supply and Right of First Refusal  Agreement.  Oxus shall have executed
and delivered to  MedSolutions a supply and right of first refusal  agreement in
the form attached hereto as Exhibit G.

     7.03  Conditions to  Obligations of SteriLogic  and the  Shareholders.  The
obligation of SteriLogic and the Shareholders to effect the Merger is subject to
the satisfaction of the following conditions unless waived by SteriLogic and all
of the Shareholders:

     (a) Representations  and Warranties.  The representations and warranties of
MedSolutions  and the Merger Sub set forth in this  Agreement  shall be true and
correct in all material respects as of the date of this Agreement and (except to
the extent such  representations  speak as of an earlier date) as of the Closing
Date  as  though  made  on and as of  the  Closing  Date,  except  as  otherwise
contemplated by this Agreement,  and SteriLogic shall have received certificates
signed on behalf of  MedSolutions  and the Merger Sub by the  President  of each
respective company to such effect.

     (b)  Performance  of  Obligations  of  MedSolutions  and  the  Merger  Sub.
MedSolutions  and the  Merger  Sub shall  each have  performed  in all  material
respects all  obligations  required to be performed by them under this Agreement
at or prior to the Closing Date, and SteriLogic shall have received certificates
signed on behalf of  MedSolutions  and the Merger Sub by the  President  of each
respective company to such effect.

     (c) Closing Documents. SteriLogic shall have received such certificates and
other  closing  documents  from  MedSolutions  and the Merger Sub as counsel for
SteriLogic shall reasonably request.

                                       27
<PAGE>

     (d)  Pending  Litigation.  There  shall  not be  any  litigation  or  other
proceeding  pending or  threatened to restrain or  invalidate  the  transactions
contemplated  by this  Agreement,  which,  in the sole  reasonable  judgment  of
SteriLogic,  made in good  faith,  would  make the  consummation  of the  Merger
imprudent.

                                  ARTICLE VIII

                            TERMINATION AND AMENDMENT

     8.01 Termination. This Agreement may be terminated at any time prior to the
Effective Time:

     (a) By mutual consent of MedSolutions and SteriLogic;

     (b)  By   MedSolutions   if  there  has  been  a  material  breach  of  any
representation, warranty, covenant or agreement on the part of SteriLogic or any
Shareholder  set forth in this  Agreement,  or by SteriLogic if there has been a
material breach of any  representation,  warranty,  covenant or agreement on the
part of  MedSolutions  or the Merger Sub, which breach has not been cured within
ten (10)  Business  Days  following  receipt by the  breaching  party of written
notice of such breach (or if cure is impossible within such ten (10) day period,
begin to take all applicable actions within such ten (10) day period to cure the
breach,  but in no event shall any party have more than 20 days to cure any such
breach);

     (c) By either  MedSolutions  or SteriLogic  if any permanent  injunction or
other order of a court or other competent authority  preventing the consummation
of the Merger shall have become final and non-appealable;

     (d) By  MedSolutions  in the  event  that  any  Shareholder  exercises  any
dissenter's  or appraisal  rights  applicable to his or her shares of SteriLogic
Common Stock with respect to the Merger; or

     (e) By either  MedSolutions or SteriLogic if the Merger shall not have been
consummated on or before August 31, 2006.

     8.02 Effect of  Termination.  In the event of termination of this Agreement
by either MedSolutions or SteriLogic as provided in Section 8.01, this Agreement
shall forthwith become void and there shall be no liability or obligation on the
part of any party  hereto.  In such event,  all costs and  expenses  incurred in
connection with this Agreement and the transactions contemplated hereby shall be
paid by the party  incurring  such  expenses.  Upon  termination , all books and
records delivered by any party to the other party shall be promptly returned.

     8.03  Amendment.  This  Agreement  may be  amended  by the  mutual  written
agreement of all parties  hereto,  provided no amendment  shall be made which by
law  requires  approval by the  shareholders  of any party  without such further
approval.

                                       28
<PAGE>

     8.04  Extension;  Waiver.  At any time  prior to the  Effective  Time,  the
parties hereto may, to the extent legally  allowed,  (a) extend the time for the
performance of any of the obligations or other acts of the other parties hereto,
(b) waive any  inaccuracies  in the  representations  and  warranties  contained
herein or in any document  delivered  pursuant  hereto and (c) waive  compliance
with any of the agreements or conditions  contained herein. Any agreement on the
part of a party  hereto to any such  extension  or waiver shall be valid only if
set forth in a written instrument signed on behalf of such party.

                                   ARTICLE IX

                               GENERAL PROVISIONS

     9.01  Survival  of   Representations,   Warranties  and   Agreements.   The
representations,   warranties  and  agreements  in  this  Agreement  or  in  any
instrument  delivered  pursuant to this Agreement shall survive the Closing Date
until the second  anniversary of the Closing Date,  other than  representations,
warranties and agreements  relating to  environmental,  employee  benefit or tax
issues,  which shall not terminate until the applicable  statutes of limitations
for such claims have expired.

     9.02 Notices.  All notices and other  communications  hereunder shall be in
writing and shall be deemed given when delivered  personally,  telecopied (which
is  confirmed)  or  mailed by  registered  or  certified  mail  (return  receipt
requested) to the parties at the  following  addresses (or at such other address
for a party as shall be specified by like notice):

     If to MedSolutions         MedSolutions, Inc.
     or the Merger Sub to:      12750 Merit Drive, Park Central VII, Suite 770
                                Dallas, Texas 75251
                                Attn: Matthew H. Fleeger, President & CEO
                                Facsimile: (972) 776-8767

     With a copy to:            Steven R. Block
                                Fish & Richardson P.C.
                                1717 Main Street, Suite 5000
                                Dallas, Texas 75201
                                Facsimile: (214) 747-2091

     If to SteriLogic or:       c/o William C. Kerr
     the Shareholders:          Abele Kerr Investments, LLC
                                49 Hill 99, Woodstock, NY  12498
                                Facsimile: (845) 679-4218

     With a copy to:            Jeffrey B. Scheer, Esq.
                                Scolaro, Shulman, Cohen, Fetter & Burstein, PC
                                507 Plum Street, Suite 300
                                Syracuse, New York 13204
                                Facsimile: (315) 477-6272

                                       29
<PAGE>

     9.03  Interpretation.  When a  reference  is  made  in  this  Agreement  to
Sections,  such  reference  shall  be to a  Section  of  this  Agreement  unless
otherwise indicated.  The headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or  interpretation  of
this Agreement. Whenever the words "include", "includes" or "including" are used
in this  Agreement,  they shall be deemed to be followed  by the words  "without
limitation".  The phrase "made  available" in this Agreement shall mean that the
information  referred to has been made  available  if  requested by the party to
whom such information is to be made available.

     9.04 Counterparts. This Agreement may be executed in multiple counterparts,
including by facsimile signature, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument.

     9.05 Entire Agreement;  No Third Party Beneficiaries;  Rights of Ownership.
This Agreement  (including the documents and the instruments referred to herein)
constitutes  the entire  agreement and supersedes all prior and  contemporaneous
agreements  and  understandings,  both written and oral,  among the parties with
respect to the subject matter hereof, and, except as otherwise set forth herein,
is not  intended  to confer upon any person  other than the  parties  hereto any
rights or remedies hereunder.

     9.06 Governing Law;  Venue.  This Agreement shall be governed and construed
in  accordance  with  the  laws of the  State  of New  York  without  regard  to
principles of conflicts of law.  Venue for any action or proceeding  arising out
of or relating to this Agreement  shall be proper  exclusively in the federal or
state courts situated in the county in which the principal  executive offices or
primary residence of the respondent thereto are located.

     9.07  Reformation and  Severability.  If any provision of this Agreement is
held to be  illegal,  invalid or  unenforceable  under  present  or future  laws
effective during the term hereof:

     (a) in lieu of such illegal,  invalid,  or unenforceable  provision,  there
shall be added  automatically as a part of this Agreement a provision as similar
in terms to such illegal, invalid, or unenforceable provision as may be possible
and be legal, valid, and enforceable; and

     (b) the legality,  validity, and enforceability of the remaining provisions
hereof shall not in any way be affected or impaired thereby.

     9.08 No Remedy in Certain Circumstances. Each party agrees that, should any
court or other competent  authority hold any provision of this Agreement or part
hereof or thereof to be null, void or unenforceable,  or order any party to take
any action inconsistent  herewith or not to take any action required herein, the
other party shall not be entitled to specific  performance  of such provision or
part  hereof or thereof or to any other  remedy,  including  but not  limited to

                                       30
<PAGE>

money  damages,  for breach hereof or thereof or of any other  provision of this
Agreement or part hereof or thereof as a result of such holding or order.

     9.09 Assignment. Neither this Agreement nor any of the rights, interests or
obligations hereunder shall be assigned by any of the parties hereto (whether by
operation of law or otherwise)  without the prior  written  consent of the other
parties. Subject to the preceding sentence, this Agreement will be binding upon,
inure to the benefit of and be enforceable  by the parties and their  respective
successors and assigns.

     9.10 Headings. The headings of sections contained in this Agreement are for
convenience  only and shall not be deemed to control  or affect  the  meaning or
construction of any provision of this Agreement.

     9.11 Specific Performance. The parties hereto agree that irreparable damage
would occur in the event that any of the  provisions of this  Agreement were not
performed in accordance with their specific terms or were otherwise breached. It
is accordingly  agreed that,  except as otherwise set forth herein,  the parties
hereto shall be entitled to an injunction or injunctions to prevent  breaches of
this  Agreement and to enforce  specifically  breaches of this  Agreement and to
enforce  specifically the terms and provisions hereof in any court of the United
States or any state  having  jurisdiction,  this being in  addition to any other
remedy to which they are entitled at law or in equity.

     9.12 Court Costs and  Attorneys'  Fees.  If any action at law or in equity,
including an action for declaratory  relief,  is brought to enforce or interpret
the  provisions of this  Agreement,  the  prevailing  party shall be entitled to
recover costs of court and  reasonable  attorneys'  fees from the other party or
parties to such action,  which fees may be set by the court in the trial of such
action or may be enforced in a separate  action  brought for that  purpose,  and
which fees shall be in addition to any other relief that may be awarded.

     9.13  Expenses,  Taxes,  Etc.  Except as  otherwise  provided  herein,  the
Shareholders  shall  pay all  fees,  taxes,  and  expenses  incurred  by them or
SteriLogic in connection with this Agreement,  and  MedSolutions  and the Merger
Sub shall pay all fees and  expenses  incurred  by them in  connection  with the
transactions contemplated by this Agreement.

                                    ARTICLE X

                                   DEFINITIONS

     The following  terms as used in this Agreement  shall have the meanings set
forth below:

     "Affiliate"  shall  mean,  as to any  Person,  any  Person  controlled  by,
controlling,  or under common  control  with such Person,  and, in the case of a
Person  who  is an  individual,  a  member  of the  family  of  such  individual
consisting  of  a  spouse,  sibling,  in-law,  lineal  descendant,  or  ancestor
(including by adoption),  and the spouses of any such individuals.  For purposes
of this definition,  "control" (including the terms  "controlling",  "controlled
by" and "under common control with") of a Person means the possession,  directly
or indirectly,  alone or in concert with others, of the power to direct or cause

                                       31
<PAGE>

the direction of the management and policies of such Person, whether through the
ownership of  securities,  by  contract,  or  otherwise,  and no Person shall be
deemed in control of another solely by virtue of being a director,  officer,  or
holder of voting securities of any entity. A Person shall be presumed to control
any partnership of which such Person is a general partner.

     "Business Day" shall mean any day other than a Saturday, Sunday, or any day
on which  banks  located  in  Dallas,  Texas  are  authorized  to be  closed  by
applicable law.

     "Code"  shall mean the  Internal  Revenue  Code of 1986,  as  amended.  All
references  herein to  sections  of the Code  shall  include  any  corresponding
provision or provisions of succeeding law.

     "Environmental  Laws"  shall  mean  laws,  including,  without  limitation,
federal, state, or local laws, ordinances, rules, regulations,  interpretations,
and orders of courts or  administrative  agencies  or  authorities  relating  to
pollution,   environmental  protection,  health  and  safety,  or  similar  laws
(including,  without limitation,  ambient air, surface water, ground water, land
surface,   and  subsurface   strata),   including,   without   limitation,   the
Comprehensive  Environmental Response Compensation and Liability Act of 1980, as
amended ("CERCLA"), the Federal Clean Water Act ("CWA"), the Safe Drinking Water
Act  ("SDWA"),  the Resource  Conservation  and Recovery Act of 1976, as amended
("RCRA"),  the Clean Air Act ("CAA"), the Emergency Planning and Community Right
to Know Act  ("EPCRA"),  OSHA,  the Medical Waste Tracking Act of 1988 ("MWTA"),
the Hazardous Materials Transportation  Authorization Act of 1994 ("HMTAA"), any
regulations  issued by the Texas  Department  of Health (the  "TDH"),  the Texas
Natural Resource Conservation  Commission (the "TNRCC"), or the Texas Commission
on Environmental  Quality (the "TCEQ"),  and other laws relating to pollution or
protection   of  the   environment,   or  to  the   manufacturing,   processing,
distribution,  use, treatment, handling, storage, disposal, or transportation of
Polluting Substances.

     "Governmental  Authority"  means  any  nation  or  government,  any  state,
regional,  local,  or other  political  subdivision  thereof,  and any entity or
official   exercising   executive,   legislative,   judicial,   regulatory,   or
administrative functions of or pertaining to government.

     "Knowledge"  - An  individual  shall be  deemed  to have  "knowledge"  of a
particular fact or other matter if (i) such individual is actually aware of such
fact or other  matter,  or (ii) a person  serving in the same  capacity  as such
individual  would be  expected  to discover or  otherwise  become  aware,  after
reasonable due inquiry, of such fact or other matter in the course of performing
the official  duties of such  individual.  A  corporation  or limited  liability
company shall be deemed to have "knowledge" of a particular fact or other matter
if the executive officers of the corporation have Knowledge (as set forth above)
of such fact or other matter.

     "Material  Adverse  Effect"  means any  effect(s),  individually  or in the
aggregate,  that would be  materially  adverse  to:  (i) a party's  assets in an
amount of $10,000 or more;  or (ii) the ability of a party to timely  consummate
the transactions contemplated hereby.

                                       32
<PAGE>

     "Person" shall have the meaning given in Section  3(a)(9) of the Securities
Exchange Act of 1934, as amended,  as modified and used in Sections 13(d)(3) and
14(d)(2) of such act.

     "Polluting  Substances" shall be construed broadly to include (a) asbestos,
(b) petroleum  products or wastes,  (c) biomedical or biological wastes, and (d)
all  pollutants,  contaminants,  chemicals,  or industrial,  toxic, or hazardous
substances  or wastes  and shall  include,  without  limitation,  any  flammable
explosives,  radioactive materials, oil, hazardous materials, hazardous or solid
wastes,  hazardous or toxic substances or regulated materials defined in CERCLA,
CWA,  SDWA,  RCRA,  EPCRA,  CAA,  OSHA,  MWTA,  and  HMTAA,   and/or  any  other
Environmental Laws, as amended,  and in the regulations adopted and publications
promulgated  thereto,  including without limitation those issued by the TDH, the
TNRCC and the TCEQ; provided,  to the extent that the laws of the State of Texas
establish a meaning for "hazardous  substance,"  "hazardous  waste,"  "hazardous
materials,"  "solid  waste," or "toxic  substance,"  which is broader  than that
specified in any of CERCLA,  CWA, SDWA, RCRA,  EPCRA,  CAA, OSHA, MWTA, HMTAA or
other Environmental Laws such broader meaning shall apply.

     "Proceeding"   shall  mean  any  action,   arbitration,   audit,   hearing,
investigation,  litigation,  or suit (whether civil,  criminal,  administrative,
judicial,  or  investigative,  whether  public or private)  commenced,  brought,
conducted,  or heard by or  before,  or  otherwise  involving  any  Governmental
Authority or arbitrator.

     "Property" includes any property (whether real or personal) that SteriLogic
currently or in the past has leased, operated,  owned, or managed in any manner,
including,  without limitation,  any property acquired by foreclosure or deed in
lieu thereof and property held as security for a loan or other  indebtedness  as
of the Effective Time.

                                       33
<PAGE>

     IN WITNESS WHEREOF,  this Merger Agreement and Plan of  Reorganization  has
been signed by the parties set forth below as of the date set forth above.

                                         MEDSOLUTIONS, INC.

                                         By:      /s/ Matthew H. Fleeger
                                                  ------------------------------
                                         Name:    Matthew H. Fleeger
                                         Title:   President & CEO

                                         STERILOGIC ACQUISITION SUBSIDIARY, INC.

                                         By:      /s/ Matthew H. Fleeger
                                                  ------------------------------
                                         Name:    Matthew H. Fleeger
                                         Title:   President

                                         STERILOGIC WASTE SYSTEMS, INC.

                                         By:      /s/ William Christopher Kerr
                                                  ------------------------------
                                         Name:    William Christopher Kerr
                                         Title:   President

                                         ABELE:

                                         ABELE-KERR INVESTMENTS, LLC

                                         By:      /s/ William Christopher Kerr
                                                  ------------------------------
                                         Name:    William Christopher Kerr
                                         Title:

                                         /s/ William Christopher Kerr
                                         ---------------------------------------
                                         William Christopher Kerr

                                         /s/ Christopher S. Abele
                                         ---------------------------------------
                                         Christopher S. Abele

                                       34
<PAGE>

                                       A-1
                                    EXHIBIT A

                                  ABELE MEMBERS

William Christopher Kerr
Christopher S. Abele

                                       A-1
<PAGE>

                                    EXHIBIT B

                          FORM OF CERTIFICATE OF MERGER

                                       B-1
<PAGE>

                                    EXHIBIT C

                                  FORM OF NOTE

<PAGE>

                           CONVERTIBLE PROMISSORY NOTE
                           ---------------------------

$250,000.00                     Syracuse, New York                August 16,2006

     FOR  VALUE  RECEIVED,   the  undersigned,   MedSolutions,   Inc.,  a  Texas
corporation (the "Maker"),  hereby unconditionally  promises to pay to the order
of  Abele-Kerr  Investments,  LLC, a Delaware  limited  liability  company  (the
"Payee"), at such place as designated by the Payee, or at such other place or to
such other party or parties as may be designated by the Payee from time to time,
in lawful  money of the United  States of  America,  the  principal  amount (the
"Principal  Amount") of  $250,000.00,  subject to adjustment in accordance  with
Section  1.08  of that  certain  Merger  Agreement  and  Plan of  Reorganization
executed between the Maker, SteriLogic Acquisition Subsidiary,  Inc., SteriLogic
Waste Systems,  Inc. and the  shareholders  of SteriLogic  Waste  Systems,  Inc.
signatory  thereto as of the date hereof (the "Merger  Agreement"),  with simple
interest at an annual rate of 8.0%. All  capitalized  terms used but not defined
herein shall have the meanings ascribed to them in the Merger Agreement.

     1. Subject to adjustment as set forth below,  this  Convertible  Promissory
Note (the "Note") shall be due and payable in 12 equal  installments of interest
only in the amount of $1,666.67  each due monthly  beginning  on  September  16,
2006,  and 24 equal  installments  of  principal  and  interest in the amount of
$11,306.82 each due thereafter with the final such installment due on August 16,
2009 (the "Maturity Date").  Each date on which a payment is due,  including the
Maturity  Date,  shall be  referred  to herein as a  "Payment  Date";  provided,
however,  that if a Payment  Date  should fall on a  Saturday,  Sunday,  or bank
holiday,  then the Payment  Date shall be the next  business  day. The Maker may
prepay  any  portion  or this  entire  Note  without  penalty  at any time.  Any
prepayment  will be applied first against  accrued but unpaid  interest and then
against the  outstanding  principal  balance.  At the request of the Payee,  the
Maker may make any payments due under the Note  directly to the creditors of the
Payee. The Payee hereby acknowledges that this Note and the Principal Amount are
subject to certain offset rights by the Maker pursuant to the Merger  Agreement.
To the extent that any interest is paid on the Note and the Principal  Amount is
subsequently  reduced in accordance with the terms of the Merger Agreement,  any
interest  previously  paid in  excess  of an 8%  annual  rate of  return  on the
adjusted Principal Amount will be credited,  in the sole discretion of the Maker
and upon prior written notice to Payee,  against the future interest  payment(s)
and/or  the  Principal  Amount  such  that the  amount of  interest  paid on the
adjusted Principal Amount does not exceed 8.0%. To the extent that the Principal
Amount is  subsequently  reduced in accordance  with the Merger  Agreement,  the
amount  of each  payment  set  forth  in the  payment  schedule  above  shall be
proportionately reduced to reflect such reduction.

     2. If the Maker fails to pay the full  amount then due on any Payment  Date
and such failure  remains  uncured for a period of three calendar days following
written notice of such default by the Payee, then, at the election of the Payee,
this Note shall  immediately  become due and  payable in full,  interest on such
principal  amount and unpaid interest shall  thereafter  accrue at the lesser of
12% or the highest lawful rate  permissible  under  applicable law (the "Default
Rate"),  and the Payee  shall be  entitled  to pursue  any remedy to which it is
entitled under applicable law.

     3. The makers, signers,  sureties,  guarantors,  and endorsers of this Note
severally  waive  valuation  and  appraisal,  demand,  presentment,   notice  of
dishonor,  notice of intent to demand or accelerate  payment  hereof,  notice of
demand,  notice of acceleration,  diligence in collecting,  grace,  notice,  and
protest. If this Note is not paid when due, the Maker agrees to pay all costs of
collection,  including,  but not limited to, reasonable  attorneys' fees and all
expenses  incurred  by the  holder  hereof on  account  of any such  collection,
whether or not suit is filed hereon.

                                      C-1
<PAGE>

     4. Except as expressly set forth in Section 1 hereof,  the Maker shall have
no right of setoff, counterclaim,  recoupment or other deduction with respect to
the payment required  hereunder,  and such payment  constitutes the absolute and
unconditional obligation of the Maker.

     5. Each right and remedy available to the holder hereof shall be cumulative
of and in addition to each other such right and remedy.  No delay on the part of
the holder hereof in the exercise of any right or remedy available to the holder
hereof  shall  operate  as a waiver  thereof,  nor shall any  single or  partial
exercise  thereof  preclude other or further exercise thereof or exercise of any
other such right or remedy.

     6. Regardless of any provision contained in this Note, Payee shall never be
entitled to receive,  collect or apply,  as interest on this Note, any amount in
excess of the maximum  lawful rate permitted by applicable law and, in the event
Payee ever  receives,  collects or applies as  interest  any such  excess,  such
amount that would be excessive  interest shall be deemed a partial prepayment of
principal and treated under this Note as such by Maker.  In determining  whether
or not the interest  paid or payable on this Note  exceeds  such maximum  lawful
rate,  Maker and Payee shall, to the maximum extent  permitted under  applicable
law, (a)  characterize any  nonprincipal  payment as an expense,  fee or premium
rather than as  interest,  (b)  exclude  voluntary  prepayments  and the effects
thereof,  and (c) amortize,  prorate,  allocate and spread,  in equal parts, the
total amount of interest throughout the entire contemplated term of this Note so
that the  interest  rate does not exceed  the  maximum  lawful  rate at any time
during the entire  term of this Note.  However,  if this Note is paid in full or
all or a portion of the principal is set off under the Merger Agreement prior to
the  scheduled  maturity  hereof,  and if the  interest  received for the actual
period of existence thereof exceeds such maximum lawful rate, Payee shall refund
the amount of such excess and shall not be subject to any  applicable  penalties
provided  by any  laws for  contracting  for,  charging,  taking,  reserving  or
receiving interest in excess of such maximum lawful rate.

     7. Conversion.

        (a) Subject to and upon  compliance  with the provisions of this Section
7, the Payee shall have the right (the "Conversion  Right"),  at its option,  at
any time and from time to time on or before  August 16, 2007,  to convert all or
any  portion  of the  outstanding  principal  amount of and  accrued  but unpaid
interest on this Note into the number of fully paid and nonassessable  shares of
Common Stock,  par value $.001, of the Maker (the "Common  Stock"),  obtained by
dividing (i) the amount of this Note to be so converted,  by (ii) the Conversion
Price.  For purposes of this Note, the term  "Conversion  Price" means $1.50, as
adjusted from time to time pursuant to the provisions of Section 8 below.

        (b) In order to exercise the conversion right provided in subsection (a)
above, the Payee shall notify the Maker in writing (a "Conversion  Notice") that
the Payee elects to convert this Note or a specified  portion  thereof,  and the
Payee shall contemporaneously surrender this Note at the office of the Maker for
cancellation.  Unless the shares of Common Stock issuable upon conversion are to
be issued in the name of the Payee,  the Conversion  Notice shall be accompanied
by instruments of transfer, in a form reasonably satisfactory to the Maker, duly
executed by the Payee or its duly authorized  attorney and an amount  sufficient
to pay any transfer or similar tax (or evidence  reasonably  satisfactory to the
Maker demonstrating that such taxes have been paid).

        As promptly as  practicable  after the  compliance by the Payee with any
other  conditions  set forth in this  subsection  (b), the Maker shall issue and
shall deliver to the Payee,  or otherwise in accordance with the Payee's written
instruction,  (i) a certificate or certificates for the number of full shares of
Common Stock  issuable upon the  conversion of this Note in accordance  with the
provisions of this Section 7 (and any fractional  interest in respect of a share
of Common  Stock  arising upon such  conversion  shall be settled as provided in
subsection  (c) of this Section 7), and (ii) if  applicable,  a new Note of like

                                      C-2
<PAGE>

tenor in the  original  principal  amount equal to the portion of this Note that
has not been so converted.

        Each  conversion  of this Note  shall be  deemed  to have been  effected
immediately  prior to the close of business on the date on which the  Conversion
Notice is  received  by the Maker.  The person or persons in whose name or names
any certificate or certificates for the shares of Common Stock issuable upon any
conversion  of this Note shall be deemed to have become the holder or holders of
record of the shares of Common Stock represented  thereby at the time and on the
date  determined in accordance  with the first sentence of this  paragraph,  and
such conversion  shall be at the Conversion Price in effect at such time on such
date. All shares of Common Stock  delivered  upon  conversion of this Note shall
upon delivery be duly and validly issued and fully paid and nonassessable.

        (c) No fractional shares of Common Stock shall be issued upon conversion
of this  Note.  Instead  of any  fractional  shares of Common  Stock  that would
otherwise be issuable upon  conversion of this Note,  the Maker shall pay a cash
adjustment  in respect of such  fractional  share in an amount equal to the same
fraction of the  current  market  price (as  defined  below) per share of Common
Stock at the close of business on the day of conversion.  For the purpose of any
computation  under this paragraph  (c), the "current  market price" per share of
Common Stock on any date shall be: (A) if the principal  trading market for such
securities is a national or regional securities  exchange,  the closing price on
such exchange on such day; or (B) if sales prices for shares of Common Stock are
reported by the NASDAQ National Market System (or a similar system then in use),
the last reported sales price so reported on such day; or (C) if neither (A) nor
(B) above are  applicable,  and if bid and ask prices for shares of Common Stock
are reported in the  over-the-counter  market by NASDAQ (or, if not so reported,
by the  National  Quotation  Bureau),  the  average  of the high bid and low ask
prices so reported on such day.  Notwithstanding  the foregoing,  if there is no
reported closing price, last reported sales price, or bid and ask prices, as the
case may be, for the day in  question,  then the current  market  price shall be
determined as of the latest date prior to such day for which such closing price,
last  reported  sales  price,  or bid and ask  prices,  as the case may be,  are
available,  unless such securities have not been traded on an exchange or in the
over-the-counter  market  for 30 or more  days  immediately  prior to the day in
question,  in which case the current  market price shall be  determined  in good
faith by the Board of Directors of the Maker.

        (d) This Note does not entitle the holder hereof to any voting rights or
other rights as a member of the Maker, nor to any other rights whatsoever except
the rights herein set forth.

     8. Effect of Certain Events.

        (a) Adjustment Due to Merger,  Consolidation,  Etc. If, at any time when
any of the principal  amount of and accrued but unpaid  interest on this Note is
outstanding,  there  shall be any  merger,  consolidation,  exchange  of capital
stock,  recapitalization,  reorganization,  reclassification,  or other  similar
event, as a result of which shares of Common Stock of the Maker shall be changed
into the same or a  different  number of shares of the same or another  class or
classes of stock or securities of the Maker or another entity, including without
limitation by way of subdividing its  outstanding  shares of Common Stock into a
greater  number of shares or combining such  outstanding  shares of Common Stock
into a smaller number of shares,  or in case of any sale or conveyance of all or
substantially  all of the assets of the Maker  other than in  connection  with a
plan of complete  liquidation of the Maker, then the Payee shall thereafter have
the right to receive upon  conversion of this Note,  upon the basis and upon the
terms and  conditions  specified  herein  and in lieu of the number of shares of
Common Stock  immediately  theretofore  issuable  upon  conversion,  such stock,
securities or assets which the Payee would have been entitled to receive in such
transaction  had this  Note been  converted  in full  immediately  prior to such
transaction,  and in any such  case  appropriate  provisions  shall be made with
respect to the rights and interests of the Payee to the end that the  provisions

                                      C-3
<PAGE>

hereof  (including,  without  limitation,   provisions  for  adjustment  of  the
Conversion  Price and of the  number of shares  of Common  Stock  issuable  upon
conversion  of the Note) shall  thereafter  be  applicable,  as nearly as may be
practicable in relation to any securities or assets thereafter  deliverable upon
the conversion hereof.  The Maker shall not effect any transaction  described in
this Section 8(a) unless (i) it first gives seven (7) days prior written  notice
of the  record  date of the  special  meeting  of  shareholders  of the Maker to
approve,  or if there is no such record date, the  consummation of, such merger,
consolidation,  exchange  of capital  stock,  recapitalization,  reorganization,
reclassification or other similar event or sale of assets (during which time the
Payee  shall be  entitled  to  convert  this  Note) and (b) if  applicable,  the
resulting  successor or acquiring  entity (if not the Maker)  assumes by written
instrument  the  obligations of this Section 8(a).  The above  provisions  shall
similarly  apply to  successive  mergers,  consolidations,  exchanges of capital
stock,  recapitalizations,  reorganizations,  reclassifications or other similar
events.

        (b) Notice of  Adjustments.  Upon the  occurrence of each  adjustment or
readjustment of the Conversion Price as a result of the events described in this
Section 8, the Maker, at its expense,  shall promptly compute such adjustment or
readjustment  and prepare and furnish to the Payee a  certificate  setting forth
such adjustment or readjustment  and showing in detail the facts upon which such
adjustment or readjustment is based.  The Maker shall,  upon the written request
at any time of the Payee, but not more frequently than once during each calendar
quarter,  furnish  to such  Payee a like  certificate  setting  forth  (i)  such
adjustment or readjustment,  (ii) the Conversion Price as of a date specified in
such written  request (which shall not be a date after the date of such request)
and (iii) the number of shares of Common Stock and the amount,  if any, of other
securities or property which would be received upon conversion of the Note as of
a date  specified in such written  request  (which shall not be a date after the
date of such request).

     9. At the option of the Payee,  this Note shall become  immediately due and
payable upon the occurrence of any of the following events of default:

        (a) The  insolvency of the Maker,  the  appointment of a receiver of its
assets, or the institution of any involuntary proceeding under any bankruptcy or
insolvency law relating to the relief of debtor for the  readjustment  or relief
of  any  indebtedness  of  Maker,  whether  as  a  reorganization,  composition,
extension  or  otherwise,   which  involuntary  proceeding  is  not  terminated,
dismissed or concluded in a manner not adverse to Maker within  thirty (30) days
of the commencement of such proceeding; or

        (b) The  filing  by Maker of an  application  or an  assignment  for the
benefit of creditors or for taking advantage of the same under any bankruptcy or
insolvency law.

     10. THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE
WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT  GIVING EFFECT TO THE CONFLICT OF
LAWS RULES OR CHOICE OF LAWS RULES THEREOF.

                                      C-4
<PAGE>

            EXECUTED effective as of the date first set forth above.

                                               MAKER:

                                               MedSolutions, Inc.

                                               By:______________________________
                                               Matthew H. Fleeger, President/CEO

                                      C-5
<PAGE>

                                    EXHIBIT D

                      FORM OF SHAREHOLDER LOCK-UP AGREEMENT

<PAGE>

                                LOCK-UP AGREEMENT

MedSolutions, Inc.
12750 Merit Drive, Suite 770
Dallas, Texas   75251

Dear Sirs:

     The  undersigned,  a shareholder of  MedSolutions,  Inc., (the  "Company"),
understands  that the  Company  has  filed  with  the  Securities  and  Exchange
Commission  ("SEC") a Form 10-SB (the "Form 10-SB")  pursuant to the  Securities
Exchange Act of 1934, as amended (the "Exchange  Act"),  and as a result thereof
the Company has become a fully  reporting  Company  under the Exchange Act, thus
creating the statutory foundation for the development of a public market for the
Company's  common  stock,  par value $.001 per share (the "Common  Stock").  The
Company's  management  believes  that the Company  soon will be in a position to
have the trading of the Common Stock quoted on the OTC Bulletin Board(R),  after
certain steps are completed,  including the execution of this Lock-Up  Agreement
by a sufficient  number of the Company's  shareholders.  In  recognition  of the
benefit that the  quotation of the trading of the Common Stock would confer upon
the undersigned as a shareholder of the Company, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
undersigned   agrees  with  the  Company   that,   except  for  the   "Allowable
Transactions"  defined herein, during the period of twelve (12) months following
the date on which the  Common  Stock is  initially  quoted  on the OTC  Bulletin
Board(R) or other national exchange (the "Effective Date"), the undersigned will
not,  without the prior written consent of the Company,  directly or indirectly,
with regard to shares of Common Stock held by the  undersigned  on the Effective
Date but not shares of Common  Stock  acquired  thereafter,  (i) offer,  pledge,
sell,  contract to sell,  sell any option or contract to purchase,  purchase any
option or contract to sell, grant any option,  right or warrant for the sale of,
or otherwise  dispose of hypothecate,  or transfer any shares of Common Stock or
any securities convertible into or exchangeable or exercisable for Common Stock,
or request that the Company file any registration statement under the Securities
Act of 1933, as amended, with respect to any of the foregoing or (ii) enter into
any swap or any other agreement or any transaction  that transfers,  in whole or
in part,  directly or indirectly,  the economic  consequence of ownership of the
Common Stock,  whether any such swap or transaction is to be settled by delivery
of Common  Stock or other  securities,  in cash or otherwise  (collectively  the
"Lock-Up Provisions").

     The Company's consent, however, is not required for the following transfers
(the  "Allowable  Transactions"):  (a) after the expiration of one year from the
Effective Date, 20% of the shares of Common Stock owned by the undersigned  will
no longer be subject to the Lock-Up  Provisions;  (b) after the expiration of 90
days  following the  completion of one year from the Effective  Date, 40% of the
shares of Common Stock owned by the undersigned will no longer be subject to the
Lock-Up  Provisions;  (c)  after  the  expiration  of  180  days  following  the
completion  of one year from the  Effective  Date,  60% of the  shares of Common
Stock  owned  by the  undersigned  will no  longer  be  subject  to the  Lock-Up
Provisions;  (d) after  expiration of 270 days  following the  completion of one
year from the  Effective  Date,  80% of the shares of Common  Stock owned by the
undersigned  will no longer be  subject  to the  Lock-Up  Provisions;  (e) after
expiration  of two years from the Effective  Date,  100% of the shares of Common
Stock  owned  by the  undersigned  will no  longer  be  subject  to the  Lock-Up
Provisions; (f) a bona fide gift or gifts made by the undersigned, provided that
the donee of such  shares  of Common  Stock or  securities  convertible  into or
exchangeable  or exercisable  for any shares of Common Stock agree in writing to
be bound by the  terms  of this  letter  agreement  prior  to such  gift;  (g) a
distribution to partners or  stockholders of the undersigned  (and to any direct
or  indirect  partner  or  stockholder  thereof),  provided  that  the  ultimate
distributees  of such shares of Common Stock or securities  convertible  into or
exchangeable  or exercisable  for any shares of Common Stock agree in writing to

                                      D-1
<PAGE>

be bound by the terms of this letter  agreement prior to such  distribution;  or
(h) transfers,  without  consideration,  of shares of Common Stock or securities
convertible  into or  exchangeable or exercisable for any shares of Common Stock
to family members or to one or more trusts established for the benefit of one or
more family members, provided that the transferee of such shares of Common Stock
or securities  convertible into or exchangeable or exercisable for any shares of
Common Stock agree in writing to be bound by the terms of this letter  agreement
prior to such transfer.  The undersigned further agrees for the Company to place
a restrictive  legend on any share  certificates  representing  shares of Common
Stock that are subject to the  Lock-Up  Provisions,  and to place  stop-transfer
orders with the  Company's  transfer  agent in order to prevent the  transfer of
shares of Common Stock in contravention of the Lock-Up  Provisions.  This letter
agreement,  once executed by the undersigned  shareholder of the Company,  shall
supersede  and  replace  in its  entirety  any  prior  lock-up  arrangement  the
shareholder may have entered into with the Company.

                                            Very truly yours,

                                            SHAREHOLDER:

                                            ABELE-KERR INVESTMENTS, LLC

                                            By:
                                                --------------------------------
                                            Name:
                                                  ------------------------------
                                            Title:
                                                   -----------------------------
                                            Date:
                                                  ------------------------------

                                            MEDSOLUTIONS, INC.

                                            By:_________________________________
                                               Matthew H. Fleeger, President/CEO

                                      D-2
<PAGE>

                                    EXHIBIT E

             FORM OF NON-COMPETITION AND NON-SOLICITATION AGREEMENT

<PAGE>

                               CONFIDENTIALITY AND

                            NON-COMPETITION AGREEMENT

     This  Confidentiality  and  Non-competition  Agreement (the "Agreement") is
made   and   entered   into   as  of   ___________,   2006,   by   and   between
______________________________, an individual (the "SteriLogic Representative"),
and MedSolutions, Inc., a Texas corporation (the "Company").

                                    RECITALS:

     A. The Company is acquiring by way of merger (the  "Merger") the assets and
liabilities of SteriLogic Waste Systems,  Inc.  ("SteriLogic"),  as set forth in
that certain  Merger  Agreement and Plan of  Reorganization,  dated  __________,
2006,  (the  "Merger  Agreement")  between the Company,  SteriLogic  Acquisition
Subsidiary,  Inc.,  SteriLogic and the  Shareholders (as such term is defined in
the Merger Agreement) signatory thereto. This Agreement is ancillary to and part
of such Merger Agreement.

     B. The  SteriLogic  Representative  is an  officer,  director,  shareholder
and/or employee of SteriLogic.

     C. The SteriLogic  Representative is intimately  familiar with confidential
information and trade secrets of SteriLogic.  The SteriLogic  Representative  is
also in a position to affect the goodwill associated with SteriLogic's business.
Further,  the  SteriLogic  Representative   acknowledges  that  the  Company  is
acquiring  such  confidential  information,   trade  secrets,  and  goodwill  of
SteriLogic pursuant to the Merger Agreement.

     D. The SteriLogic  Representative's  access to and knowledge of proprietary
and  confidential  information,  trade secrets,  and goodwill of SteriLogic will
present the SteriLogic  Representative  with the  opportunity to benefit himself
and others wrongly at the expense of the Company, its customers, and SteriLogic,
if the SteriLogic  Representative does not abide by the terms of this Agreement.
If the SteriLogic  Representative  were to compete with the Company, it would be
highly  unlikely  that  the  SteriLogic   Representative  could  do  so  without
misappropriating  for himself or for any competing employer information obtained
through  his  employment  with  the  Company  or  SteriLogic,   thereby  causing
irreparable harm to the business of the Company.

     E. The  SteriLogic  Representative  will receive,  directly or  indirectly,
financial  consideration  from the Company as a result of the Merger  Agreement,
given SteriLogic  Representative's  position as a member of the sole shareholder
of SteriLogic.

     F. In addition to this  Agreement,  the  SteriLogic  Representative  may be
entering into an employment or consulting  agreement with the Company as part of
the Merger  Agreement.  If so, this Agreement is ancillary to such employment or
consulting agreement.

                                      E-1
<PAGE>

     G. For  purposes  of this  Agreement,  the term  "Company"  shall  mean and
include the Company and its  affiliates,  and all of their  direct and  indirect
subsidiaries.

                                   AGREEMENTS:

     THEREFORE,  in exchange for the consideration  contained herein, as well as
the  consideration  contained in the Merger Agreement  inuring to the SteriLogic
Representative's  benefit  as a result of such  agreement,  and  other  good and
valuable   consideration,   the  receipt  and   adequacy  of  which  are  hereby
acknowledged, the SteriLogic Representative agrees with the Company as follows:

                                    ARTICLE I

                     CONFIDENTIALITY OF COMPANY INFORMATION

     Confidentiality Agreement. The SteriLogic Representative acknowledges that,
during  the  negotiation  of the  Merger  Agreement,  during  the  course of his
employment  with,  management of or ownership of the SteriLogic,  and during the
course of his employment or consulting  relationship  with the Company,  if any,
the SteriLogic  Representative has or will become privy to certain  Confidential
Information  (hereinafter  defined) of the  Company  and/or  SteriLogic  and the
SteriLogic  Representative  agrees that he shall not,  without the prior written
consent of the Company,  at any time, whether before,  during, or after the term
of his employment with the Company, if applicable, except as required to perform
his duties of  employment  with the  Company,  use,  disseminate,  disclose,  or
communicate  any  Confidential  Information  to any  person or entity  inside or
outside the United States. As used herein, the term  "Confidential  Information"
means:  (i) all  information  about the Company  disclosed  or made known to the
SteriLogic  Representative as a direct or indirect consequence of or through the
Merger Agreement,  (ii) all information about SteriLogic disclosed or made known
to the  SteriLogic  Representative  during  the course of his  employment  with,
management of or ownership of SteriLogic,  and (iii) all  information  about the
Company  disclosed  or made known to the  SteriLogic  Representative  during the
course of his employment or consulting  with the Company,  that is not generally
known in the  industries  in  which  the  Company  or any of its  affiliates  or
subsidiaries  is  or  may  become  engaged,   including,  but  not  limited  to,
information about: (A) financial position,  product line, customers,  suppliers,
and market; (B) profit margins, pricing techniques, or pricing information as to
both purchase  prices from  suppliers  and sale prices to  customers;  (C) past,
present, or future plans with respect to the business of the Company;  (D) bids,
negotiations,  or  techniques in bidding or  negotiating,  pursuant to supplier,
wholesaler,   customer  or  other  contracts;  (E)  current  or  future  Company
advertising or promotion plans or programs;  (F) any Company system,  procedure,
or administrative operations; (G) Company's structure,  employees, or processes;
and (H) present or future  plans for the  extension  of the present  business or
commencement  of a new business by the Company or any  subsidiary or division of
the Company.  Confidential  information  shall exclude  information that: (w) is
already known by the receiving party prior to disclosure by the other party from
a source other than the disclosing party and not under a duty of confidentiality
to the  Company,  (x) is in the public  domain,  (y)  ceases to be  confidential
through no fault of the receiving  party, or (z) is  independently  developed by
the receiving party.

                                      E-2
<PAGE>

                                   ARTICLE II

                            NON-COMPETITION COVENANTS

     2.01  Term of  Non-Competition.  The  "Term of  Non-Competition"  means the
period  beginning  on the date hereof and  continuing  for a period of two years
following  the date that the Merger  becomes  effective  pursuant  to the Merger
Agreement.

     2.02 No  Business  Competition.  During  the Term of  Non-Competition,  the
SteriLogic  Representative  will  not,  in  the  States  of  Texas  ,  Oklahoma,
Louisiana,  Arkansas,  Kansas,  Missouri,  New York,  New  Jersey,  Connecticut,
Massachusetts,  Delaware, Pennsylvania, New Hampshire, Vermont and Rhode Island,
own, manage,  operate,  join, control or participate in, directly or indirectly,
or be a partner or  shareholder  of  (except  for  shares in the  Company),  any
business engaged in the (A) regulated medical waste transportation business, and
(B) sharps management business (collectively,  the "Competing Businesses"),  and
the  SteriLogic  Representative  shall not  render  assistance  or advice to any
person which is so engaged; provided however, that the passive ownership of less
than 5% of the equity securities of a  publicly-traded  company that is involved
in any of the foregoing businesses shall be permissible under this Section 2.02.

     2.03  No   Solicitation  of  Company's   Customers.   During  the  Term  of
Non-Competition,  the  SteriLogic  Representative  shall  not  induce,  request,
advise, attempt to influence, or solicit, directly or indirectly,  any person or
entity  that is an actual or  prospective  customer  of the  Company at any time
during the Term of  Non-Competition to buy products or services from a competing
business.  It is  understood  that this Section 2.03 shall be in addition to and
not construed as a limitation upon any other covenant in Article II hereof.

         2.04 No Solicitation of Employees. During the Term of Non-Competition,
the SteriLogic Representative hereby agrees not to induce, directly or
indirectly, any person who is an employee of the Company to leave the employment
of the Company.

     2.05  Tolling of Term.  If,  during any  calendar  month within the Term of
Non-Competition,  the SteriLogic  Representative  is not in compliance  with the
terms  of  this   Article  II,  the  Company   shall   provide  the   SteriLogic
Representative  with notice of such  non-compliance  and shall be  entitled  to,
among other remedies, compliance by the SteriLogic Representative with the terms
of this Article II for an additional  number of calendar  months that equals the
number of calendar  months during which such  noncompliance  occurred.  The term
"Term of Non-Competition" shall also include this additional period.

     2.06   Reasonableness  of  Restrictions.   The  SteriLogic   Representative
acknowledges that the geographic boundaries, scope of prohibited activities, and
time  duration of the  provisions of this Article II are  reasonable  and are no
broader than are necessary to maintain the  confidentiality  of the Confidential
Information  and the goodwill  associated with the Company's goods and services,
and to protect the other legitimate business interests of the Company, including
its goodwill and the intent of the Merger Agreement.

                                      E-3
<PAGE>

                                   ARTICLE III

                                  MISCELLANEOUS

     3.01 Continuing  Obligation.  If the SteriLogic  Representative also has an
employment   or  consulting   agreement   with  the  Company,   the   SteriLogic
Representative's  obligations under this Agreement shall continue whether or not
the SteriLogic  Representative's employment or consulting with the Company shall
be terminated  voluntarily or involuntarily,  with or without cause, and whether
or not the SteriLogic  Representative  or the Company breaches the employment or
consulting  agreement between the SteriLogic  Representative and the Company, if
any.

     3.02 Parties  Bound.  This  Agreement  shall be binding upon the SteriLogic
Representative,    the    SteriLogic    Representative's    heirs,    executors,
administrators,  and assigns and shall inure to the benefit of the Company,  its
successors, and assigns.

     3.03 Counterparts. This Agreement may be executed in multiple counterparts,
including  by  facsimile  signature,  each of  which  shall be  deemed  to be an
original but all of which together shall constitute one and the same instrument.

     3.04 Waiver. The Company may waive compliance with any of the agreements or
conditions  contained  herein.  Any  agreement on the part of the Company to any
such waiver shall be valid only if set forth in an instrument in writing  signed
by the Company.

     3.05  Entirety  and  Amendments.  This  Agreement  constitutes  the  entire
understanding  between the parties  with respect to the subject  matter  hereof,
supersedes all prior agreements or understandings relating to the subject matter
hereof, and may be modified or amended only by an instrument in writing executed
by the parties hereto.

     3.06  Headings.  The heading  contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or  interpretation  of
this Agreement.

     3.07  Governing  Law.  THE LAW OF THE  STATE OF NEW YORK  WILL  GOVERN  THE
INTERPRETATION,  VALIDITY  AND EFFECT OF THIS  AGREEMENT  WITHOUT  REGARD TO THE
PLACE OF EXECUTION OR THE PLACE OF PERFORMANCE THEREOF.

     3.08 Invalid  Provisions and Request for  Reformation.  If any provision of
this Agreement  (including,  without  limitation,  any provision relating to the
activities  covered  by, or time  period of, the  non-competition  covenants  of
Article II) is held to be illegal,  invalid,  or unenforceable  under present or
future laws  effective  during the term hereof,  such  provision  shall be fully
severable;  this  Agreement  shall be construed and enforced as if such illegal,
invalid,  or unenforceable  provision had never comprised a part hereof; and the
remaining  provisions  shall  remain in full  force and  effect and shall not be
affected by the illegal, invalid, or unenforceable provision or by its severance
herefrom.  Furthermore,  in lieu  of such  illegal,  invalid,  or  unenforceable
provision,  there  shall be added  automatically  as a part of this  Agreement a

                                      E-4
<PAGE>

provision  as  similar  in  terms to such  illegal,  invalid,  or  unenforceable
provision as may be possible  that is legal,  valid,  and  enforceable,  and the
Company hereby requests the court or any arbitrator to whom disputes relating to
this Agreement are submitted to reform the otherwise  unenforceable  covenant in
accordance with the preceding provision.

            [The remainder of this page is left intentionally blank.]

                                      E-5
<PAGE>

     IN WITNESS WHEREOF,  the undersigned have executed this Agreement as of the
date first written above.

                                            MEDSOLUTIONS, INC.

                                            By:
                                               ---------------------------------
                                               Matthew H. Fleeger, President/CEO

                                            STERILOGIC REPRESENTATIVE

                                            By:_________________________________
                                               [Printed name]

                                      E-6
<PAGE>

                                    EXHIBIT F

                          FORM OF CONSULTING AGREEMENT

<PAGE>

                              CONSULTING AGREEMENT

     This  Agreement  (this  "Agreement")  is made and entered  effective  as of
_______, 2006 (the "Effective Date"), by and between MedSolutions, Inc., a Texas
corporation  (the  "Company"),   and  Consular,  LLC,  a  _____________  limited
liability company (the "Consultant").

                                    RECITALS:

     A. The Company is acquiring by way of merger (the  "Merger") the assets and
liabilities of SteriLogic Waste Systems,  Inc.  ("SteriLogic"),  as set forth in
that certain  Merger  Agreement and Plan of  Reorganization,  dated  __________,
2006,  (the  "Merger  Agreement")  between the Company,  SteriLogic  Acquisition
Subsidiary,  Inc.,  SteriLogic and the  Shareholders (as such term is defined in
the Merger Agreement) signatory thereto. This Agreement is ancillary to and part
of such Merger Agreement.

     B. The  principal of the  Consultant is an officer,  director,  shareholder
and/or employee of SteriLogic.

     C. The principal of the  Consultant  has certain  skills,  experience,  and
abilities that may be valuable to the  successful  transition of the business of
SteriLogic  to the Company and to the success of the  Company's  operations  and
future profitability;

     D. The Company desires to retain the Consultant to render certain  specific
consulting and advisory services for the Company on the terms and conditions set
forth in this  Agreement,  and the  Consultant  desires  to be  retained  by the
Company on such terms and conditions; and

     E. The  Company  and the  Consultant  desire  to set  forth  the  terms and
conditions  pursuant to which the Consultant will render consulting and advisory
services to the Company.

     NOW,  THEREFORE,  in  consideration  of the  foregoing  premises and of the
mutual  covenants  and  undertakings  contained  herein,  and for other good and
valuable  consideration,  the  receipt  and  sufficiency  of  which  are  hereby
acknowledged, the parties to this Agreement hereby agree as follows:

                                    ARTICLE I

                           PERFORMANCE OF THE SERVICES

     1.01  Engagement and Duties.  The Company and the  Consultant  hereby agree
that  during  the Term  (defined  below),  the  Consultant  shall  provide  such
consulting  services  as are  assigned or  delegated  to the  Consultant  by the
President of the Company (the "Services") to assist in the orderly transition of
the  business  of  SteriLogic  to the  Company  as  contemplated  by the  Merger
Agreement.  During the Term (as defined below), the Consultant shall devote such
business time, attention, skill and energy to the business of the Company as the
President of the Company shall request in his reasonable  discretion,  and shall

                                      F-1
<PAGE>

assume and perform to the best of his ability the Services. The Consultant shall
report to the President of the Company during the Term.

     1.02 Term and  Termination.  This Agreement shall continue and be in effect
from the Effective Date for a term of 12 months (the "Term").

     1.03  Remuneration.  The Consultant shall submit to MedSolutions,  promptly
after the end of each calendar month during the Term, a detailed written invoice
(a "Monthly  Invoice")  of all  Services  provided and the number of hours spent
providing  such  Services  to  MedSolutions   during  such  calendar  month.  In
consideration  for performance of the Services,  the Consultant  shall be paid a
fee of $31.25 per hour during the Term,  payable on the 10th  calendar day after
MedSolutions'  receipt of each Monthly  Invoice.  The Company  shall provide the
Consultant with no additional compensation, benefits or insurance.

     1.04 Independent Contractor Status.

     (a)  Consultant  may  use  any  ethical  and  lawful  means  necessary  and
appropriate to perform his obligations under this Agreement;  provided, however,
that in no event shall  Consultant  take any action that would be adverse to the
business  interests of the Company or that may subject Consultant or the Company
to civil or  criminal  liability.  Consultant  agrees to comply in full with all
applicable laws, rules and regulations and Consultant  covenants and agrees that
he has no  undisclosed  interest  that would  conflict  in any  manner  with the
performance of services under this Agreement.  In recognition of the independent
contractor  status of  Consultant,  the  Company  agrees  that,  subject  to the
covenants  contained  in this  Agreement  and that certain  Confidentiality  and
Non-Competition  Agreement  entered  into by and  between  the  Company  and the
Consultant as of the date hereof, Consultant may engage in additional activities
and may allocate his time between Consultant's  obligations under this Agreement
and such other activities in any manner Consultant deems appropriate, so long as
Consultant's  obligations  under this Agreement are fully satisfied.  Consultant
shall be responsible for all expenses  incurred by the Consultant in furtherance
of his provision of the Services,  except for expenses that are  pre-approved in
writing  by the  Company.  Consultant  will  have the sole  right to  supervise,
manage,  control,  and  direct  the  performance  of  the  details  incident  to
Consultant's duties described in this Agreement.

     (b)  Consultant  is and shall be an  independent  contractor  with the sole
right to supervise,  manage, operate, control, and direct the performance of the
details incident to Consultant's duties under this Agreement.  Nothing contained
in this Agreement  shall be deemed or construed to create a partnership or joint
venture, to create the relationships of an employer-employee or principal-agent,
or to otherwise create any liability for or obligation of the Company whatsoever
with respect to the indebtedness,  liabilities, and obligations of Consultant or
any other  party.  Consultant  specifically  understands  and  agrees  that this
Agreement shall not be deemed to grant or imply that Consultant is authorized to
sign,  contract,  deal,  or  otherwise  act in the name of or on  behalf  of the
Company,  except as is  expressly  authorized  in  writing by the  Company.  The
Company  shall not be  obligated  to  maintain  any  insurance  for  Consultant,
including,  but not limited to, medical,  dental, life, or disability insurance.
Consultant stipulates and agrees that he will not be eligible for any employment
benefits from the Company.  To the extent Consultant employs others in providing

                                      F-2
<PAGE>

services under this Agreement,  Consultant  agrees to comply with all applicable
workers'   compensation  laws,  to  provide  satisfactory   assurances  of  such
compliance  to the Company on request,  and to indemnify  and hold  harmless the
Company from any liability or obligation  in  connection  therewith.  CONSULTANT
SHALL NOT BE CONSIDERED  UNDER THE  PROVISIONS OF THIS AGREEMENT OR OTHERWISE AS
HAVING  THE  STATUS OF AN  EMPLOYEE  OF THE  COMPANY,  OR AS BEING  ENTITLED  TO
PARTICIPATE IN ANY LIFE,  ACCIDENT OR HEALTH  INSURANCE PLANS,  PENSION,  STOCK,
BONUS,  THRIFT  OR  PROFIT  SHARING  PLANS,  WORKER'S   COMPENSATION   BENEFITS,
VACATION/SICK  LEAVE BENEFITS,  OR ANY SIMILAR BENEFITS WHICH MAY BE PROVIDED BY
THE COMPANY FOR ITS EMPLOYEES,  AND CONSULTANT  HEREBY EXPRESSLY WAIVES ANY SUCH
ENTITLEMENT, IF SUCH ENTITLEMENT EXISTS OR IS DEEMED TO EXIST.

     1.05 Taxes and Withholding.  The Consultant hereby  acknowledges and agrees
that, as an independent contractor,  he is legally required to determine and pay
his own estimated federal income taxes, FICA (including FICA-matching),  and all
applicable federal and state payroll, excise, workman's compensation,  and other
withholdings owed, or claimed to be owed, by Consultant by reason or arising out
of Consultant's  relationship  with the Company pursuant to this Agreement,  and
Consultant shall indemnify and hold the Company  harmless from and against,  and
shall defend the Company against, any and all losses,  damages,  claims,  costs,
penalties,  liabilities,  and  expenses  arising out of or incurred  because of,
incident to, or otherwise with respect to any such taxes. The Consultant further
acknowledges that the Company is legally obligated,  and shall endeavor to issue
timely,  a yearly Form 1099 to the  Consultant,  and a Form 1096 to the Internal
Revenue Service, reporting the full amount of fees paid to the Consultant during
the reporting period.

     1.06 Confidentiality, Non-Competition and Non-Solicitation. Other than such
actions as are required in discharging his  obligations  under this Agreement in
the ordinary course of business,  the Consultant and his affiliates hereby agree
to abide by the terms and conditions of the  Confidentiality and Non-Competition
Agreement  entered into by between the Company and the Consultant as of the date
hereof which is ancillary to this Agreement.

                                   ARTICLE II

                                  MISCELLANEOUS

     2.01 Further Assurances Each party hereto,  without further  consideration,
shall,  at  the  reasonable   request  of  any  other  party  hereto  after  the
consummation of the  transactions  contemplated  by this Agreement,  execute and
deliver any  instruments of conveyance,  assignment,  transfer,  assumption,  or
other  instrument or document and take such other  actions,  as such other party
may  reasonably   request  to  more  effectively   consummate  the  transactions
contemplated by this Agreement.

     2.02  Severability.  If any  provision  of  this  Agreement  is  held to be
illegal,  invalid,  or unenforceable under any present or future law, and if the
rights or  obligations  of either of the parties  hereto would not be materially
and adversely  affected  thereby,  (a) such provisions shall be fully severable;

                                      F-3
<PAGE>

(b) this Agreement shall be construed and enforced as if such illegal,  invalid,
or unenforceable provisions had never comprised a part hereof; (c) the remaining
provisions of this Agreement shall remain in full force and effect and shall not
be  affected by the  illegal,  invalid,  or  unenforceable  provision  or by its
severance;  (d) in lieu of such illegal,  invalid,  or unenforceable  provision,
there shall be added  automatically as a part of this Agreement a legal,  valid,
and  enforceable  provision  as similar in terms to such  illegal,  invalid,  or
unenforceable provision as may be possible.

     2.03  Assignment.  This Agreement shall be assigned and transferred to, and
shall be binding  upon and shall inure to the benefit of, any  successor  of the
Company,  and any such  successor  shall be deemed  substituted as the "Company"
hereunder  for all purposes.  As used in this  Agreement,  the term  "successor"
shall mean any person, firm,  corporation,  or business entity that at any time,
whether  by  merger,  spin  off,  purchase,   or  otherwise,   acquires  all  or
substantially  all of the assets or  business  of the  Company.  Notwithstanding
anything  contained  herein to the contrary,  the Parties  acknowledge that this
Agreement  is based on the  particular  abilities of  Consultant  and may not be
assigned, in whole or in part, by Consultant.

     2.04 Number and Gender of Words.  Any  references  herein to the  masculine
gender, or to the masculine form of any noun, adjective, or possessive, shall be
construed  to include the  feminine or neuter  gender and form,  and vice versa.
Additionally,  whenever  used  herein,  the singular  number  shall  include the
plural, and the plural number shall include the singular.

     2.05 Headings. The headings contained in this Agreement are for purposes of
reference only and shall not limit or otherwise affect the meaning of any of the
provisions contained herein.

     2.06  GOVERNING  LAW. THIS  AGREEMENT  SHALL BE GOVERNED BY THE LAWS OF THE
STATE OF NEW YORK WITHOUT  GIVING EFFECT TO THE CHOICE OR CONFLICT OF LAWS RULES
THEREOF OR OF ANY STATE.

     2.07 Legal Remedies;  Specific  Performance.  The parties to this Agreement
understand  and agree that it will be impossible to measure in money the damages
that  may  accrue  to a  party  to  this  Agreement  or to its  heirs,  personal
representatives,  or  assigns  by  reason  of a failure  to  perform  any of the
obligations set forth in this  Agreement,  and that any such money damages would
be an insufficient remedy for such failure of performance. Therefore, each party
hereto hereby  consents to be subject to the remedy of specific  performance  of
any  provision  of this  Agreement  if such party shall have been found to be in
violation of such provision by any court of competent jurisdiction. If any party
or its  heirs,  personal  representatives,  or assigns  institute  any action or
proceeding to specifically enforce the provisions of this Agreement,  any person
against whom such action or  proceeding  is brought  hereby  waives the claim or
defense in such action or proceeding  that such party has an adequate  remedy at
law, and such person shall not urge in any such action or  proceeding a claim or
defense that such remedy at law exists.

     2.08 Court Costs and  Attorneys'  Fees.  If any action at law or in equity,
including an action for  declaratory  relief or an action  brought under Section
2.06  hereof,  is  brought  to  enforce  or  interpret  the  provisions  of this

                                      F-4
<PAGE>

Agreement,  the prevailing party shall be entitled to recover costs of court and
reasonable attorneys' fees from the other party or parties to such action, which
fees may be set by the court in the trial of such action or may be enforced in a
separate action brought for that purpose, and which fees shall be in addition to
any other relief that may be awarded.

     2.09 Inurement.  Subject to the restrictions against transfer or assignment
as herein contained, the provisions of this Agreement shall inure to the benefit
of, and shall be binding  on, the  assigns,  successors  in  interest,  personal
representatives, estates, heirs, and legatees of each of the parties hereto.

     2.10 Notices. Any notice or other communication required or permitted to be
given  hereunder  shall be in writing and shall be sent by first class U.S. mail
or  facsimile  transmission,  or  delivered  by hand or by  overnight or similar
delivery  service,  fees prepaid,  to the party to whom it is to be given at the
address of such party set forth  below or to such  other  address  for notice as
such party shall provide in accordance with the terms of this section. Except as
otherwise specifically provided in this Agreement, notice so given shall, in the
case of notice given by certified mail (or by such comparable  method) be deemed
to be given and received  three  business  days after the time of  certification
thereof  (or  comparable  act),  in the case of  notice  so  given by  overnight
delivery service, on the date of actual delivery,  and, in the case of notice so
given by  facsimile  transmission  or personal  delivery,  on the date of actual
transmission or, as the case may be, personal delivery.

     If to the Company:                MedSolutions, Inc.
                                       Attn: President
                                       12750 Merit Drive
                                       Park Central VII, Suite 770
                                       Dallas, Texas 75251
                                       Facsimile: (972) 931-2550

     If to the Consultant:             ---------------------------

                                       ---------------------------

                                       ---------------------------

                                       ---------------------------

                                       Facsimile: (___) ___ - ____

     2.11  Waivers.  No waiver of any  provision or condition of this  Agreement
shall be valid  unless  executed  in writing and signed by the party to be bound
thereby,  and then only to the extent specified in such waiver. No waiver of any
provision or condition of this  Agreement  shall be construed as a waiver of any
other  provision or condition of this  Agreement,  and no present  waiver of any
provision or condition of this  Agreement  shall be construed as a future waiver
of such provision or condition.

     2.12 Amendment. This Agreement may be amended only by the unanimous written
consent of the parties hereto.

                                      F-5
<PAGE>

     2.13 Entire  Agreement.  This Agreement  contains the entire  understanding
between the parties hereto concerning the subject matter contained herein. There
are no representations,  agreements,  arrangements,  or understandings,  oral or
written,  between or among the parties hereto  relating to the subject matter of
this Agreement that are not fully expressed herein.

     2.14   Construction   of  Agreement.   Each  party  and  its  counsel  have
participated  fully in the review and  revision of this  Agreement.  Any rule of
construction  to the effect  that  ambiguities  are to be  resolved  against the
drafting party shall not apply in the interpretation of this Agreement.

     2.15 Execution. Each party to this Agreement hereby represents and warrants
to the other  parties  hereto  that such  party has full power and  capacity  to
execute,  deliver, and perform this Agreement,  which has been duly executed and
delivered  by, and which  evidences  the valid and binding  obligation  of, such
party   enforceable   in  accordance   with  its  terms  subject  to  applicable
liquidation, conservatorship, bankruptcy, insolvency, reorganization, or similar
laws affecting the enforcement of creditor's right's from time to time in effect
and to general principles of equity.

     2.16  Multiple  Counterparts.  This  Agreement  may be executed in multiple
counterparts, including by facsimile signature, each of which shall be deemed to
be an original,  but all of which  together  shall  constitute  one and the same
instrument.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                      F-6
<PAGE>

     IN WITNESS WHEREOF, the parties to this Agreement have set their respective
hands as of the Effective Date.

                                        THE COMPANY:

                                        MEDSOLUTIONS, INC.

                                        By:
                                           -------------------------------------
                                           Matthew H. Fleeger
                                           President and Chief Executive Officer

                                        THE CONSULTANT:

                                        CONSULAR, LLC

                                        By:__________________________________
                                        William Christopher Kerr
                                        Title:

                                      F-7
<PAGE>

                                    EXHIBIT G

               FORM OF SUPPLY AND RIGHT OF FIRST REFUSAL AGREEMENT

<PAGE>

                   SUPPLY AND RIGHT OF FIRST REFUSAL AGREEMENT
                   -------------------------------------------

     This  Supply  and  Right of First  Refusal  Agreement  (this  "Agreement"),
executed to be effective as of August 16, 2006 (the "Effective  Date"),  is made
and entered into by and between  MedSolutions,  Inc., a Texas  corporation,  for
itself and on the behalf of its affiliates (collectively,  "MedSolutions"),  and
Oxus Environmental, LLC, a Delaware limited liability company ("Oxus").

                                   WITNESSETH:

     WHEREAS,  MedSolutions  is  acquiring  through  a merger  transaction  (the
"Merger")  the  assets  and  liabilities  of  SteriLogic  Waste  Systems,   Inc.
("SteriLogic"),  as set  forth  in that  certain  Merger  Agreement  and Plan of
Reorganization,  dated of even date  herewith (the "Merger  Agreement")  between
MedSolutions,  SL Acquisition Subsidiary,  Inc., SteriLogic and the shareholders
of SteriLogic signatory thereto. This Agreement is ancillary to and part of such
Merger Agreement; and

     WHEREAS, Oxus is an affiliate of SteriLogic; and

     WHEREAS,  each of MedSolutions  and Oxus is required to execute and deliver
to one another this Agreement as a condition  precedent to the  consummation  of
the transactions contemplated by the Merger Agreement.

     NOW,  THEREFORE,  in consideration of the foregoing premises and the mutual
undertakings  and covenants  set forth  herein,  and for other good and valuable
consideration,  the receipt and sufficiency of which is hereby acknowledged, the
parties to this Agreement hereby agree as follows:

                                    ARTICLE I
                                    ---------

     1.01 Supply of Products and  Services.  During the period  beginning on the
Effective Date and ending on the third anniversary thereof,  MedSolutions hereby
grants Oxus the right to purchase products and services from MedSolutions of the
nature offered by SteriLogic's  Systems division prior to the Merger,  solely to
the extent that  MedSolutions  continues to offer such products and services for
sale, at MedSolutions'  cost plus 15%; provided,  however,  that Oxus shall only
purchase  such  products  and services  for use in  connection  with Oxus' Maine
operating  division.  In the event that Oxus uses such products and services for
purposes  other  than  in  connection  with  Oxus'  Maine  operating   division,
MedSolutions  shall  have the  right,  exercisable  in its sole  discretion,  to
terminate its any or all of its obligations pursuant to this Section 1.01 at any
time. In the event of the consummation of a Transaction (as such term is defined
in Section 2.01 hereof),  MedSolutions shall have the right,  exercisable in its
sole discretion, to terminate its any or all of its obligations pursuant to this
Section  1.01  at any  time  on or  after  the  date  of  consummation  of  such
Transaction.

     1.02 Lease of PIWS Mobile  Treatment Unit.  During the period  beginning on
the Effective  Date and ending on the third  anniversary  thereof,  MedSolutions
hereby  grants Oxus the right to lease one (1) PIWS mobile  treatment  unit from

                                      G-1
<PAGE>

MedSolutions on terms mutually  acceptable to MedSolutions  and Oxus,  including
without  limitation,  terms providing for a flat monthly usage fee for such unit
and an  additional  variable  fee based on pounds  processed  through such unit;
provided,  however,  that Oxus shall only use such unit in connection with Oxus'
Maine  operating  division.  In the event that Oxus uses such unit for  purposes
other than in connection with Oxus' Maine operating division, MedSolutions shall
have the right, exercisable in its sole discretion,  to terminate its any or all
of its obligations  pursuant to this Section 1.02 at any time. Oxus may exercise
its right to lease such unit pursuant to this Section 1.02 by providing  written
notice to  MedSolutions  of its election to exercise such right. In the event of
the  consummation  of  a  Transaction,   MedSolutions   shall  have  the  right,
exercisable in its sole  discretion,  to terminate its  obligations  pursuant to
this  Section  1.02 at any time on or after  the  date of  consummation  of such
Transaction.

                                   ARTICLE II

     2.01 Right of First Refusal. For the 36-month period immediately succeeding
the Effective Date, in the event that Oxus or its members receive or negotiate a
bona fide,  noncollusive  offer (the "Offer") with or from any independent third
party (an "Offeror") to acquire all or substantially all of the capital stock of
Oxus or Oxus' assets relating to its Maine operating division, or any affiliated
successor  to the  assets  thereof,  whether  through a  merger,  consolidation,
purchase,  or other  transaction  (the "Offeror  Transaction"),  and Oxus or its
members accept or desire to accept such Offer,  Oxus hereby grants  MedSolutions
an exclusive  and  irrevocable  right and option (the  "Option") to acquire such
stock or assets at the purchase price (subject to adjustment as set forth below)
and on the terms offered by the Offeror (the "Transaction").  In the event of an
Offer, Oxus shall be required to inform the Offeror of MedSolutions' Option, and
shall further be required to inform the Offeror that  MedSolutions  reserves the
right,  to be exercised  in  MedSolutions'  sole  discretion,  to cease  selling
products  and  services  to  Oxus  (or its  successor  pursuant  to the  Offeror
Transaction,  as the case may be) in the event that  MedSolutions  elects not to
exercise its Option. In the event of an Offer, Oxus shall provide written notice
of the terms of such Offer (the "Offer  Notice") to  MedSolutions  within  three
days of its receipt of such Offer, providing the name of the Offeror, the amount
and/or  nature of the capital  stock or assets which the Offer is for, the Offer
price,  proof the Offer was made,  any other material terms of the Offer and the
structure  of the  Offeror  Transaction.  MedSolutions  shall  have 30 days (the
"Exercise  Period")  from the date of its receipt of the Offer  Notice from Oxus
(the "Offer Notice Date") to exercise its Option by providing  written notice of
its  exercise of such  Option to Oxus (the  "Exercise  Notice").  Any failure by
MedSolutions  to provide an Exercise  Notice to Oxus during the Exercise  Period
shall  constitute  a  rejection  of the  Option and Oxus  shall be  entitled  to
consummate the Offeror  Transaction with the Offeror on terms and conditions not
less favorable to Oxus than those described in the Offer Notice. In the event of
MedSolutions'   timely  delivery  to  Oxus  of  an  Exercise  Notice,  Oxus  and
MedSolutions shall have 60 days from the date of delivery of the Exercise Notice
to Oxus to  negotiate  in good  faith and  execute  a  definitive  agreement  on
substantially the same terms and conditions as set forth in the Offer Notice for
the  acquisition  of the  capital  stock or assets  related  to the Offer and to
consummate such acquisition;  provided, however, that the purchase price offered
to Oxus or its  members  in  connection  with the Offer  shall be  appropriately
adjusted such that the purchase  price to be paid by  MedSolutions  accounts for
any benefit received by Oxus on account of the discounted  products and services

                                      G-2
<PAGE>

sold to Oxus by  MedSolutions  pursuant to Article I of this  Agreement.  In the
event that MedSolutions delivers the Exercise Notice within the Exercise Period,
but the parties fail to consummate the Transaction within such 60-day period due
to the sole  fault of  MedSolutions,  Oxus shall be  entitled  to enter into the
Offeror Transaction with the Offeror.

                                   ARTICLE II

                                  MISCELLANEOUS

     3.01 Headings. The headings of sections contained in this Agreement are for
convenience  only and shall not be deemed to control  or affect  the  meaning or
construction of any provision of this Agreement.

     3.02 Specific Performance. The parties hereto agree that irreparable damage
would occur in the event that any of the  provisions of this  Agreement were not
performed in accordance with their specific terms or were otherwise breached. It
is accordingly agreed that the parties hereto shall be entitled to an injunction
or injunctions to prevent breaches of this Agreement and to enforce specifically
breaches of this Agreement and to enforce  specifically the terms and provisions
hereof in any court of the United States or any state having jurisdiction,  this
being in  addition to any other  remedy to which they are  entitled at law or in
equity.

     3.03  GOVERNING  LAW;  VENUE.  THIS  AGREEMENT  SHALL  BE  GOVERNED  BY AND
CONSTRUED IN  ACCORDANCE  WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT  GIVING
EFFECT TO THE  CONFLICT OF LAWS RULES OR CHOICE OF LAWS RULES  THEREOF OR OF ANY
STATE.  VENUE FOR ANY ACTION OR  PROCEEDING  ARISING  OUT OF OR RELATING TO THIS
AGREEMENT SHALL BE PROPER EXCLUSIVELY IN THE FEDERAL OR STATE COURTS SITUATED IN
THE COUNTY IN WHICH THE PRINCIPAL  EXECUTIVE  OFFICES OF THE RESPONDENT  THERETO
ARE LOCATED.

     3.04 Court Costs and  Attorneys'  Fees.  If any action at law or in equity,
including an action for declaratory  relief,  is brought to enforce or interpret
the  provisions of this  Agreement,  the  prevailing  party shall be entitled to
recover costs of court and  reasonable  attorneys'  fees from the other party or
parties to such action,  which fees may be set by the court in the trial of such
action or may be enforced in a separate  action  brought for that  purpose,  and
which fees shall be in addition to any other relief that may be awarded.

     3.05  Assignability  and Binding Effect.  This Agreement shall inure to the
benefit  of  and be  binding  upon  the  parties  hereto  and  their  respective
successors,  heirs,  and permitted  assigns.  This  Agreement and the rights and
obligations  hereunder shall not be assignable without the prior written consent
of all  parties  hereto;  provided,  however,  that  MedSolutions  may assign or
delegate any or all of its rights and  obligations  hereunder to an affiliate at
any time without the prior written consent of Oxus.

                                      G-3
<PAGE>

     3.06  Amendments.   This  Agreement  may  not  be  modified,   amended,  or
supplemented  except by an  agreement  in writing  signed by all of the  parties
hereto.

     3.07 Notices.  All notices and other  communications  hereunder shall be in
writing and shall be deemed given when delivered  personally,  telecopied (which
is  confirmed)  or  mailed by  registered  or  certified  mail  (return  receipt
requested) to the parties at the  following  addresses (or at such other address
for a party as shall be specified by like notice):

     If to MedSolutions:     MedSolutions, Inc.
                             12750 Merit Drive, Park Central VII, Suite 770
                             Dallas, Texas 75251
                             Attn: Matthew H. Fleeger, President & CEO
                             Facsimile: (___) ___ - ____

     With a copy to:         Steven R. Block
                             Fish & Richardson P.C.
                             1717 Main Street, Suite 5000
                             Dallas, Texas 75201
                             Facsimile: (214) 747-2091

     If to Oxus:
                             -----------------------------------

                             -----------------------------------
                             Attn:
                                   -----------------------------
                             Facsimile:
                                        ------------------------

     With a copy to:         Jeffrey B. Scheer, Esq.
                             Scolaro, Shulman, Cohen, Fetter & Burstein, PC
                             507 Plum Street, Suite 300
                             Syracuse, New York 13204
                             Facsimile: (315) 477-6272

     3.08 Third  Parties.  Nothing  herein  expressed  or implied is intended or
shall be  construed  to confer upon or give to any person other than the parties
hereto and their successors,  heirs or permitted assigns, any rights or remedies
under or by reason of this Agreement.

     3.09  Number and Gender of Words.  When the  context  so  requires  in this
Agreement, words of gender shall include either or both genders and the singular
number shall include the plural.

     3.10 Entire Agreement. This Agreement shall constitute the entire agreement
between the parties hereto with respect to the transactions  contemplated hereby
and shall supersede all prior or  contemporaneous  negotiations,  understandings
and  agreements.  There are no  representations,  agreements,  arrangements,  or
understandings, oral or written, between or among the parties hereto relating to
the subject matter of this Agreement that are not fully expressed herein.

                                      G-4
<PAGE>

     3.11  Multiple  Counterparts.  This  Agreement  may be executed in multiple
counterparts, including by facsimile signature, each of which shall be deemed to
be an  original  but all of which  together  shall  constitute  one and the same
instrument.

                                      G-5
<PAGE>

     IN WITNESS  WHEREOF,  the parties  hereto have caused this  Agreement to be
executed as of the date first above written.

                                    MEDSOLUTIONS, INC.

                                    By:     ____________________________________
                                    Name:   Matthew H. Fleeger
                                    Title:  President and CEO

                                    OXUS ENVIRONMENTAL, LLC

                                    By:     ____________________________________
                                    Name:   W.C. Kerr
                                    Title:  President

                                      G-6<PAGE>

EXHIBIT 10.1

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE "SECURITIES ACT"), OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED,
SOLD, PLEDGED, OR OTHERWISE TRANSFERRED OR DISPOSED OF UNLESS AND UNTIL THIS
NOTE IS REGISTERED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS
OR AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE.

                                 PROMISSORY NOTE
                                 ---------------

$1,000,000.00                                                    August 15, 2006

         For value received, Airgate Technologies, a Texas Corporation
("AIRGATE"), and The X-Change Corporation, a Nevada corporation ("X-CHANGE", and
collectively with Airgate, "BORROWERS"), jointly and severally promise to pay to
the order of Melissa CR 364 Ltd., a Texas limited Partnership ("LENDER") at 416
CR 364 Melissa, TX 75454, or at such other address as Lender shall from time to
time specify in writing, the principal sum of One Million AND NO/100 DOLLARS
($1,000,000.00) (the "MAXIMUM AMOUNT"), or so much thereof as may be advanced by
Lender pursuant to the terms hereunder, in legal and lawful money of the United
States of America, with interest on the outstanding principal from the date
advanced until paid at the rate set out below. Interest shall be computed on a
per annum basis of a year of 360 days, and for the actual number of days
elapsed. All payments to Lender under this Note shall be without offset.

         1. LOAN; ADVANCES.

                  (a) LOAN. Subject to Borrowers' compliance with the terms of
         this Note, Lender agrees to make loan advances (each such advance, a
         "LOAN" and collectively, the "LOANS") to Airgate or on behalf of
         Airgate from time to time in immediately available funds, in the amount
         determined pursuant to Section 1(b), until a Maximum amount of One
         Million ($1,000,000.00) Dollars has been reached. Notwithstanding
         anything contained herein to the contrary, Lender shall not be
         obligated to make a Loan requested under Section 1(b) if the
         outstanding principal amount of all Loans made by Lender, after giving
         effect to the proposed Loan requested by Borrower, shall exceed the
         Maximum Amount. At the date of the execution of this promissory note
         the initial advance covering all previous notes due from borrower is
         acknowledged to be Seven Hundred Fifty Eight Thousand and Eighty Five
         and no/100 dollars ($758,085.00). This amount includes any and all
         interest due on the previous notes which was due through August 1,
         2006.

                  (b) REQUEST FOR LOAN. Airgate shall provide X-Change and
         Lender with a request for each draw. Subject to Borrowers compliance
         with the terms of this Note, Lender agrees to make a Loan equal to the
         amount of each draw by wire transfer or check in immediately available
         funds no later than five (5) days following Lender's receipt of such
         request.

                                       1
<PAGE>

                  (c) RECORDATION OF AMOUNT OF ADVANCES. In the absence of
         manifest error, the books and records of Lender shall be conclusive and
         binding upon Borrowers as to the principal balance of the Loan
         outstanding at any time and the amount of accrued interest thereon.

         2. INTEREST RATE. Interest on the outstanding and unpaid principal
balance hereof shall be computed at a per annum rate equal to the lesser of (a)
10.00%, or (b) the Maximum Legal Rate (as defined below). In no event will the
interest rate stated herein be an amount less than the Applicable Federal Rate
(the "AFR") proscribed by the Internal Revenue Service for this Note to have
adequate stated interest for debt instruments of the same nature and term as
this Note. Notwithstanding anything herein to the contrary, should the interest
rate stated herein be insufficient to meet the required AFR, then such interest
rate will be adjusted accordingly retroactive to the date of this Note. If this
Note has already been repaid in full, then an additional interest amount will be
computed in accordance with the immediately preceding sentence and immediately
paid by Borrowers, along with interest on the amount of such additional interest
through the date of payment at a rate per annum equal to the then existing
interest rate on this Note.

         3. PAYMENT OF LOAN AND INTEREST. Borrowers hereby unconditionally
promise to pay to Lender the then unpaid principal amount, together with all
unpaid accrued interest, of the Loans as follows:

                  (a) This Note is due and payable as follows, to-wit: Interest
         only for a period of 24 months when the entire balance shall be due and
         payable. The first such payment due and payable on the 1st day of
         November, 2006, and a like installment shall be due and payable on the
         same day of each succeeding quarter thereafter until the total
         principal of $ any outstanding amount up to the maximum loan amount is
         paid in full. If each payment is not paid on time, the remaining
         balance will be subject to the maximum amount of interest permitted by
         the Laws of the State of Texas.

                  (b) To induce the lender to enter into this loan, the
         borrower's have pledged 100% of the outstanding stock in AirGATE
         Technologies Inc, a Texas Corporation (AGTI), doing business at 710
         Century Blvd, Allen, TX 75013. Lender agrees that the AGTI stock will
         be returned The X-Change Corporation when this note is paid in full.

                  (c) At the sole discretion of lender the principal amount and
         any accrued interest that is due and payable on this note may be
         converted into restricted common stock of The X-Change Corporation, at
         any time during the term of this note. The conversion rate shall be at
         50% of the closing price of The X-Change Corporation common stock on
         August 11, 2006. Said closing price was $1.65.

         4. ADJUSTMENT UPON REORGANIZATION OF COMPANY. In case of any capital
reorganization, conversion, reclassification or recapitalization of the Common
Stock or in case X-Change consolidates or merges with or into, or transfers or
leases all or substantially all its assets to, any other person or entity, upon
consummation of any such transaction the payment obligations of Borrowers
contained in SECTION 3 shall become payable in the kind and amount of
securities, cash or other assets that the holder of Shares receives as
consideration for such transaction, or as a result of its ownership of the
Shares in connection with such transaction.

                                       2
<PAGE>

         5. OPTIONAL PREPAYMENT. Borrowers reserve the right to prepay, prior to
maturity, all or any part of the principal of this Note without penalty. Any
prepayments shall be applied first to accrued interest and then to principal.

         6. REPRESENTATIONS AND WARRANTIES OF X-CHANGE. X-Change hereby
represents and warrants to Lender that, the statements contained in the
following paragraphs of this Section 6 are all true and correct as of the date
hereof:

                  (a) X-Change is a corporation duly organized, validly existing
         and in good standing under the laws of the State of Nevada and has all
         requisite corporate power and authority to carry on its business as now
         conducted.

                  (b) X-Change has all requisite legal and corporate power to
         enter into, execute and deliver this Note. This Note is a valid and
         binding obligation of X-Change, enforceable in accordance with its
         terms, except as the same may be limited by bankruptcy, insolvency,
         moratorium, and other laws of general application affecting the
         enforcement of creditors' rights.

                  (c) All corporate and legal action on the part of X-Change,
         its officers, directors and shareholders necessary for the execution
         and delivery of this Note and the performance of X-Change's obligations
         hereunder have been taken.

                  (d) No consent, approval, order or authorization of, or
         designation, registration, declaration or filing with, any federal,
         state, local or other governmental authority on the part of X-Change is
         required in connection with the valid execution and delivery of this
         Note.

         7. REPRESENTATIONS AND WARRANTIES OF AIRGATE. Airgate hereby represents
and warrants to Lender that, the statements contained in the following
paragraphs of this Section 7 are all true and correct as of the date hereof:

                  (a) Airgate has all requisite legal power to enter into,
         execute and deliver this Note. This Note is a valid and binding
         obligation of Airgate, enforceable in accordance with its terms, except
         as the same may be limited by bankruptcy, insolvency, moratorium, and
         other laws of general application affecting the enforcement of
         creditors' rights.

                  (b) No consent, approval, order or authorization of, or
         designation, registration, declaration or filing with, any federal,
         state, local or other governmental authority on the part of Airgate is
         required in connection with the valid execution and delivery of this
         Note.

                                       3
<PAGE>

         8. REPRESENTATIONS AND WARRANTIES OF LENDER. Lender represents and
warrants to Borrowers as of the date hereof as follows:

                  (a) This Note is made with Lender in reliance upon Lender's
         representation to Borrowers, evidenced by Lender's execution of this
         Note, that Lender is acquiring the Note for investment for Lender's own
         account, not as nominee or agent, for investment and not with a view
         to, or for resale in connection with, any distribution or public
         offering thereof within the meaning of the Securities Act or the laws
         of the State of Texas. Lender has the full right, power, authority and
         capacity to enter into and perform this Note and the Note will
         constitute a valid and binding obligation upon Lender, except as the
         same may be limited by bankruptcy, insolvency, moratorium, and other
         laws of general application affecting the enforcement of creditors'
         rights.

                  (b) Lender (i) has such knowledge and experience in financial
         and business matters as to be capable of evaluating the merits and
         risks of Lender's prospective investment in the Note; (ii) has the
         ability to bear the economic risks of Lender's prospective investment;
         (iii) has had all questions which have been asked by Lender
         satisfactorily answered by each Borrower; (iv) has not been offered the
         Note by any form of advertisement, article, notice or other
         communication published in any newspaper, magazine, or similar media or
         broadcast over television or radio, or any seminar or meeting whose
         attendees have been invited by any such media. Lender represents and
         warrants that it is an "accredited investor" within the meaning of Rule
         501(a) of Regulation D of the Securities Act; and (v) has acquired this
         Note for investment purposes and not with a view toward the
         distribution or sale hereof.

         9. EVENTS OF DEFAULT. Without notice or demand (which are hereby
waived), the entire unpaid principal balance of and all accrued interest on this
Note shall immediately become due and payable at the option of the holder hereof
upon the occurrence of any one or more of the following events of default
(individually or collectively, herein called an "EVENT OF DEFAULT"):

                  (a) Borrowers shall fail to make any payment, return, forfeit
         or transfer any Shares, or issue any Common Stock on the date by which
         such payment, return, forfeiture, transfer or issuance is due pursuant
         to the terms provided herein (whether due at stated maturity, on
         demand, upon acceleration or otherwise) and such failure shall not be
         remedied within ten (10) days after the occurrence thereof;

                  (b) Any representation or warranty made by any Borrower in
         this Note or in any certificate or document furnished in connection
         with this Note or therewith shall prove to have been untrue or
         incorrect in any material respect when made;

                  (c) Any Borrower shall fail or neglect to perform, keep or
         observe any covenant contained in this Note and such default shall not
         be remedied within thirty (30) days after such Borrower learns of such
         failure to comply, whether by its own discovery or through notice from
         Lender (other than a breach caused solely by a violation by Lender of
         its obligations under this Note); or

                                       4
<PAGE>

                  (d) Any Borrower shall (i) become insolvent within the meaning
         of the Bankruptcy Code of the United States, as amended, (ii) admit in
         writing its or his inability to pay or otherwise fail to pay its or his
         debts generally as they become due, (iii) voluntarily seek, consent to,
         or acquiesce in the benefit or benefits of any Debtor Relief Law
         (meaning the Bankruptcy Code of the United States, as amended, and all
         other applicable liquidation, conservatorship, bankruptcy, moratorium,
         rearrangement, receivership, insolvency, reorganization, or similar
         debtor relief laws from time to time in effect affecting the rights of
         creditors generally), or (iv) be made the subject of any proceeding
         provided for by any Debtor Relief Law that could suspend or otherwise
         affect any of the rights of the holder hereof.

         10. REMEDIES UPON AN EVENT OF DEFAULT. Upon the occurrence of an Event
of Default, the holder of this Note may (a) offset against this Note any sum or
sums owed by the holder hereof to any Borrower, and (b) proceed to protect and
enforce its rights either by suit in equity and/or by action at law, or by other
appropriate proceedings, whether for the specific performance of any covenant or
agreement contained in this Note or any document or instrument executed and
delivered by any Borrower in connection with this Note or in aid of the exercise
of any power or right granted by this Note or any document or instrument
executed and delivered by any Borrower in connection with or securing this Note
or to enforce any other legal or equitable right of the holder of this Note.

         11. DEFAULT RATE. Following the occurrence and during the continuance
of an Event of Default, all unpaid principal and interest shall bear interest at
a rate per annum equal to the lesser of (a) the Maximum Legal Rate, or (b)
eighteen percent (18%).

         12. NO USURY INTENDED; USURY SAVINGS CLAUSE. In no event shall interest
contracted for, charged or received hereunder, plus any other charges in
connection herewith which constitute interest, exceed the maximum interest
permitted by applicable law (the "MAXIMUM LEGAL RATE"). The amounts of such
interest or other charges previously paid to the holder of the Note in excess of
the amounts permitted by applicable law shall be applied by the holder of the
Note to reduce the principal of the indebtedness evidenced by the Note, or, at
the option of the holder of the Note, be refunded. To the extent permitted by
applicable law, determination of the legal maximum amount of interest shall at
all times be made by amortizing, prorating, allocating and spreading in equal
parts during the period of the full stated term of the loan and indebtedness,
all interest at any time contracted for, charged or received from any Borrower
hereof in connection with the loan and indebtedness evidenced hereby, so that
the actual rate of interest on account of such indebtedness is uniform
throughout the term hereof.

         13. GOVERNING LAW. This Note shall be governed by and construed in
accordance with the domestic laws of the State of Texas without giving effect to
any choice or conflict of law provision or rule (whether of the State of Texas
or any other jurisdiction) that would cause the application of the laws of any
jurisdiction other than the State of Texas. Any legal action or proceeding with
respect to this Note may be brought in any Texas state or federal court sitting

                                       5
<PAGE>

in Dallas County, Texas, and, by execution and delivery of this Note, each
Borrower and Lender hereby accept for itself and in respect of its property,
generally and unconditionally, the jurisdiction of the aforesaid courts. Each
Borrower hereby irrevocably waives any objection, including, without limitation,
any objection to the laying of venue or based on the grounds of forum non
conveniens, which it may now or hereafter have to the bringing of any such
action or proceeding in such respective jurisdictions.

         14. NOTICES. All notices, requests, demands, claims, and other
communications hereunder will be in writing and shall be deemed duly given (a)
when sent if by confirmed facsimile; (b) the next business day if by overnight
delivery; or (c) five business days after the date when sent if by registered or
certified mail, return receipt requested, postage prepaid, and addressed to the
intended recipient as set forth below:

        IF TO BORROWERS:                        COPY TO:
        ----------------                        --------

        710 Century Parkway                     Baker & McKenzie LLP
        Allen, Texas  75013                     2001 Ross Avenue, Suite 2300
        Attention: Michael Sheriff              Dallas, TX 75201
        Telephone:        (972) 747-0051        Attention: W. Crews Lott
        Facsimile:        (972) 359-6334        Telephone:        (214) 978-3000
                                                Facsimile:        (214) 978-3099
        IF TO LENDER:
        -------------

        Melissa 364 Ltd.
        416 CR 364
        Melissa, TX 75454

        Telephone:        (972) 837-4272

         15. CAPTIONS. The captions in this Note are inserted for convenience
only and are not to be used to limit the terms herein.

         16. CUMULATIVE RIGHTS. No delay on the part of the holder of this Note
in the exercise of any power or right under this Note, or under any document or
instrument executed in connection herewith, shall operate as a waiver thereof,
nor shall a single or partial exercise of any other power or right. Enforcement
by the holder of this Note of any security for the payment hereof shall not
constitute any election by it of remedies so as to preclude the exercise of any
other remedy available to it.

         17. WAIVER. Each Borrower, and each surety, endorser, guarantor, and
other party ever liable for the payment of any sum of money payable on this
Note, jointly and severally waives (in each case only after the occurrence and
during the continuation of an Event of Default) demand, presentment, protest,
notice of protest, notice of intent to accelerate, notice of acceleration and
any and all lack of diligence or delay in collection or the filing of suit
hereon which may occur; and agrees that its liability on this Note shall not be
affected by any renewal or extension in the time of payment hereof, by any
indulgences, or by any release or change in any security for the payment of this
Note.

                                       6
<PAGE>

         18. SEVERABILITY. If any provision of this Note shall be held to be
unenforceable by a court of competent jurisdiction, such provision shall be
severed from this Note and the remainder of this Note shall continue in full
force and effect.

         19. NO THIRD PARTY BENEFICIARIES. This Note shall not confer any rights
or remedies upon any person other than the parties and their respective
successors and permitted assigns.

         20. JOINT AND SEVERAL OBLIGATIONS. Notwithstanding anything herein to
the contrary, the indebtedness evidenced by this Note and all other obligations
hereunder are joint and several obligations of Borrowers, and Lender may seek
payment in full of any amounts due hereunder from any Borrower. Each Borrower
agrees that his joint and several obligations hereunder shall be absolute and
unconditional and shall not be discharged until all obligations hereunder have
been paid in full.

         21. COUNTERPARTS. This Note may be executed in one or more
counterparts, each of which shall be deemed an original but all of which
together will constitute one and the same instrument.

         22. ASSIGNMENT. This Note, or any portion hereof, may not be assigned
by any Borrower or by Lender without the consent of each other Borrower and
Lender, and any such assignment made without such consent will be void.

         23. ATTORNEYS' FEES AND COSTS. Borrowers jointly and severally agree to
pay Lender's reasonable attorneys' fees and costs incurred in collecting or
attempting to collect this Note, whether by suit or otherwise.

         24. PREVIOUS ADVANCES. Each Borrower and Lender acknowledge and agree
that Lender has previously advanced Loans equal to $758,085 in the aggregate
prior to the date hereof, and that such Loans shall be deemed to be Loans
advanced hereunder and shall be payable pursuant to the terms hereof.

         25. NO ORAL AGREEMENTS. THIS NOTE CONSTITUTES A WRITTEN LOAN AGREEMENT
AND REPRESENTS THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE
CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL
AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE
PARTIES.

         26. FURTHER ASSURANCES. Borrowers shall, from time to time at the
request of Lender, do all further acts and things as may in the reasonable
opinion of Lender be necessary or advisable to effectuate the transaction and
other matters contemplated hereby, including, without limitation, in connection
with the transfer of shares of Common Stock.

                                       7
<PAGE>

                            INTENTIONALLY LEFT BLANK

                                                     BORROWERS:
                                                     ----------

                                                     THE X-CHANGE CORPORATION,
                                                     a Nevada corporation

                                                     By:
                                                         -----------------------
                                                         Name:Michael Sheriff
                                                     Title:President and CEO

                                                     AirGATE Technologies, Inc.
                                                     a Texas corporation

                                                     By:
                                                         -----------------------
                                                          Name:Michael Sheriff
                                                     Title:President and CEO

                                                     l

                                                     LENDER:
                                                     -------

                                                     By:
                                                         -----------------------
                                                          Name: Melissa CR 364
                                                     Ltd., a Texas Limited
                                                     Partnership

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]